10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q 

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended September 30, 2017
[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period __________  to  __________
	Commission File Number:000-54767

Rich Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	46-3259117
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

9595 Wilshire Blvd., Suite 900

Beverly Hills, California 90212

(Address of principal executive offices)

(424) 230-7001

(Registrant’s telephone number)

_____________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

[ ] Large accelerated filer [ ] Non-accelerated filer [ ] Accelerated filer [X] Smaller reporting company
[ ] Emerging growth company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

The number of shares outstanding of common stock as of December 29, 2017 was 955,027,821.  

	TABLE OF CONTENTS	Page
PART I - FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	5
Item 4:	Controls and Procedures	5
PART II - OTHER INFORMATION
Item 1:	Legal Proceedings	6
Item 1A:	Risk Factors	6
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3:	Defaults Upon Senior Securities	11
Item 4:	Mine Safety Disclosures	11
Item 5:	Other Information	11
Item 6:	Exhibits	11

Unless otherwise indicated, in this Form 10-Q, references to “we,” “our,” “us,” the “Company,” or the “Registrant” refer to Rich Pharmaceuticals Inc., a Nevada corporation.

FORWARD-LOOKING STATEMENTS

This Report on Form 10-Q contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking statements included in this report.  Such statements may be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue,” or similar terms, variations of such terms or the negative of such terms.  Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements.  Such statements address future events and conditions concerning, among others, capital expenditures, earnings, litigation, regulatory matters, liquidity and capital resources, and accounting matters.  Actual results in each case could differ materially from those anticipated in such statements by reason of factors such as future economic conditions, changes in consumer demand, legislative, regulatory and competitive developments in markets in which we operate, results of litigation, and other circumstances affecting anticipated revenues and costs. You should not place undue reliance on these forward-looking statements.

The forward-looking statements made in this report on Form 10-Q relate only to events or information as of the date on which the statements are made in this report on Form 10-Q.  Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.  You should read this report and the documents that we reference in this report, including documents referenced by incorporation, completely and with the understanding that our actual future results may be materially different from what we anticipate.

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Balance Sheets as of September 30, 2017 (Unaudited) and March 31, 2017 (Audited)	F - 1
Condensed Statements of Operations (Unaudited) for the three and six months ended September 30, 2017 and 2016	F - 2
Condensed Statements of Cash Flows (Unaudited) for the three and six months ended September 30, 2017 and 2016	F - 3
Condensed Notes to Financial Statements (Unaudited)	F - 4 - F - 20

3

RICH PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS 

	September 30, 2017 (Unaudited)			March 31, 2017 (Audited)
ASSETS
Current Assets
Cash and equivalents	$	24,974		$	40,903
Notes receivable		15,300			10,000
Total Current Assets		40,274			50,903
Property and equipment, net		1,538			2,125
Securities available for sale		15,000			—
TOTAL ASSETS	$	56,812		$	53,028
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable	$	312,134		$	296,635
Accounts payable – related party		286,700			53,000
Accrued expenses		1,188,520			937,783
Due to related parties		54,001			49,395
Note payable		920,000			920,000
Convertible notes payable, net of debt discount of $174,572 and $356,819		688,984			514,075
Derivative liabilities		1,912,905			2,607,959
Total Current Liabilities		5,363,244			5,378,847
Long-term Liabilities
Convertible notes payable, net of debt discount		—			—
Derivative liabilities		—			—
Total Long-term Liabilities		—			—
Total Liabilities		5,363,244			5,378,847
Commitments and Contingencies		—			—
Stockholders’ Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively		6,000			6,000
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 880,678,573 and 101,446,215 shares issued and outstanding,		880,678			101,446
Common stock to be issued		100,000			—
Additional paid-in capital		6,657,296			7,011,504
Accumulated deficit		(12,950,406	)		(12,444,769	)
Total Stockholders’ Deficit		(5,306,432	)		(5,325,819	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	56,812		$	53,028

See accompanying notes to financial statements.

F-1

RICH PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) 

	Three months ended September 30, 2017			Three months ended September 30, 2016			Six months ended September 30, 2017			Six months ended September 30, 2016
REVENUES	$	115,000		$	—		$	115,000		$	—
OPERATING EXPENSES
Consulting expenses		95,375			5,850			100,000			16,075
Office expenses		31,828			35,472			98,231			70,046
Depreciation expense		313			431			586			862
Wages and taxes		139,963			96,001			277,752			191,956
Professional fees		39,942			34,158			104,699			88,401
Regulatory fees		4,182			2,686			38,491			9,529
Research and development		833			—			148,406			—
Stock-based compensation		—			—			—			—
Travel, meals and entertainment		19,027			8,197			34,773			21,403
TOTAL OPERATING EXPENSES		331,463			182,795			802,938			398,272
LOSS FROM OPERATIONS		(216,463	)		(182,795	)		(687,938	)		(398,272	)
OTHER INCOME (EXPENSE)
Amortization of debt discount		(330,681	)		(25,786	)		(681,011	)		(72,360	)
Change in value of derivative liability		2,465,455			51,683			1,068,465			168,454
Derivative expense		—			—			(249,457	)		—
Interest expense		(121,909	)		(109,466	)		(168,682	)		(142,475	)
Interest expense – related party		(155	)		(155	)		(308	)		(230	)
Gain (Loss) on extinguishment of debt		—			—			213,294			—
		2,012,710			(83,724	)		182,301			(46,611	)
INCOME/(LOSS) BEFORE PROVISION FOR INCOME TAXES		1,796,247			(266,519	)		(505,637	)		(444,883	)
PROVISION FOR INCOME TAXES		—			—			—			—
NET INCOME/(LOSS)	$	1,796,247		$	(266,519	)	$	(505,637	)	$	(444,883	)
NET INCOME/(LOSS) PER SHARE: BASIC AND DILUTED	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED		602,711,661			23,050,307			397,523,663			19,935,954

See accompanying notes to financial statements.

F-2

RICH PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Six months ended September 30, 2017			Six months ended September 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$	(505,637	)	$	(444,883	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		586			863
Amortization of debt discount		681,011			72,360
Change in value of derivative liability		(1,068,465	)		(168,454	)
Derivative expense		249,457			—
Gain on extinguishment of debt		(213,294	)		—
Warrants issued for services		—			—
Stock-based compensation		—			—
Changes in operating assets and liabilities:
Decrease in prepaid expenses		—			2,800
Increase (decrease) in bank overdraft		—			(800	)
Increase in accounts payable		249,199			111,299
Increase in accrued expenses		313,250			236,377
Net Cash Used by Operating Activities		(293,893	)		(190,438	)
CASH FLOWS FROM INVESTING ACTIVITY:
Increase in notes receivable		(5,300	)		—
Increase in stock held for investment		(15,000	)
Net Cash Used by Investing Activities		(20,300	)		—
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties		4,606			(37,812	)
Proceeds from sale of common stock and warrants		100,000			—
Proceeds from issuance of note payable		—			—
Proceeds from issuance of convertible notes payable		193,658			228,250
Net Cash Provided by Financing Activities		298,264			190,438
Net Increase (Decrease) in Cash and Cash Equivalents		(15,929	)		—
Cash and cash equivalents, beginning of period		40,903			—
Cash and cash equivalents, end of period	$	24,974		$	—
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	—		$	—
Income taxes paid	$	—		$	—
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable	$	—		$	900,000
Warrants issued for accrued expenses	$	—		$	—
Original issue discounts recorded on notes payable	$	10,000		$	—
Debt discounts recorded on convertible notes payable	$	498,764		$	—
Debt/interest converted into common stock and contributed capital	$	277,208		$	70,478

See accompanying notes to financial statements.

F-3

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”).

On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000.

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.)

On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

F-4

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2017 and March 31, 2017 the Company had $24,974 and $40,903, respectively, of unrestricted cash.

Basis of Presentation

The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.

Long-Lived and Intangible Assets

The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

F-5

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value of Financial Instruments (continued)

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;

Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company did not have any level 3 financial instruments at September 30, 2017 or March 31, 2017. As of September 30, 2017, the securities available for sale were considered a level 1 item (see note 3); the derivative liabilities were considered a level 2 item (see Note 9).

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company has made all adjustments necessary for a fair presentation of the interim financial information and all such adjustments are normal and recurring in nature, as required under ASC Topic 270.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Research and Development

The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts).

F-6

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Basic Loss Per Share

The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

NOTE 2 – PROPERTY AND EQUIPMENT

Property and equipment, recorded at cost, consisted of the following as of September 30, 2017 and March 31, 2017:

	September 30, 2017			March 31, 2017
Computer equipment & furniture	$	5,160		$	5,160
Less: accumulated depreciation		(3,622	)		(3,035	)
Property and equipment, net	$	1,538		$	2,125

The useful life of the computer equipment and furniture is 3 years.

Depreciation expense was $586 and $1,606 for the periods ended September 30, 2017 and March 31, 2017, respectively.

NOTE 3 – SECURITIES AVAILABLE FOR SALE

The Company received 15,000,000 common stock shares of an entity that is majority owned by a non-majority stockholder of the Company designating the two entities as under common control. This transaction is partial payment for access to the Company’s intellectual property. This holding represents about 11% of the ownership of the invested company. The Company classifies its equity securities held as available for sale, and as such, they are carried at fair value. Changes in fair value of available for sale securities will be reported as a component of other comprehensive income and evaluated at the end of each quarter. The shares currently do not have a firm quoted trading price and thus they are carried at their par value until such time as the shares have established a trading price in the market. It should be noted that recording this transaction at par value of the securities is the same treatment recorded by the issuing company due to the lack of active market and lack of transferability of the shares.

F-7

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 4 – INTANGIBLE ASSETS

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.

On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.

NOTE 5 – ACCRUED EXPENSES

Accrued expenses consisted of the following as of September 30, 2017 and March 31, 2017:

	September 30, 2017		March 31, 2017
Wages and taxes	$	1,012,457	$	829,231
Accrued interest		176,063		108,552
Total accrued expenses	$	1,188,520	$	937,783

NOTE 6 – RELATED PARTY DEBT AND TRANSACTIONS  

During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest and has an original due date of January 8, 2016. There is a total due of $12,280 as of September 30, 2017 and March 31, 2017. Interest accrued on the note as of September 30, 2017 was $1,211. The Company is in default on the balance of this note.

During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of September 30, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company.

Periodically, related parties incur expenses for the Company and are expected to be repaid for those expenditures. As of September 30, 2017, the balance owed to related parties for these types of expenses is $40,160. These liabilities do not have stated interest rates or due dates, but are payable at the discretion of the Company.

F-8

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 6 – RELATED PARTY DEBT AND TRANSACTIONS (CONTINUED)

The Company has a consulting agreement with a related party to provide research into new technologies as well as essential development of current products. The amounts owed to this related party for past work is a part of accounts payable and totals $286,700 and $53,000 for the periods ending September 30, 2017 and March 31, 2017, respectively.

On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended through November 2018; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $137,500 and $275,000 for the six months ended September 30, 2017 and the twelve months ended March 31, 2017 (respectively) as a result of this agreement, these amounts contribute to the $737,611 and $645,945 of officer compensation which is included in accrued expenses, as of September 30, 2017 and March 31, 2017.

The intangible assets (as described in note 4) were made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement accounts for all of the $115,000 of revenue recognized by the Company.

NOTE 7 – NOTE PAYABLE

On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $120,082 as of September 30, 2017.

On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $969 as of September 30, 2017.

NOTE 8 – CONVERTIBLE NOTE PAYABLE     

On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, incurring additional financing fees of $11,819. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

F-9

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 8 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $8,838, (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. Accrued interest was $4,602 as of September 30, 2017. The Company is in default on the balance of this note.

On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2017.

On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of March 31, 2017. On February 22, 2017, this note was purchased for a renegotiated face value of $20,900, incurring additional financing fees of $5,150. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

F-10

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 8 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2017 the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. As of March 31, 2017 the principal and accrued interest balance is $0.

On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $20,280, incurring additional financing fees of $1,280. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on December 29, 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $1,609. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. On April 4, 2017, this note was purchased for a renegotiated face value of $71,457. (details provided under the note dated April 4, 2017 below). As of September 30, 2017 the principal and accrued interest balance is $0.

On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on February 25, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2017 the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $10,755. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

F-11

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 8 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on March 24, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $7,500. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $38,107, incurring additional financing fees of $8,107. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, incurring additional financing fees of $49,964. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017 the accrued interest balance is $5,695.

On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. During the period ended September 30, 2017, the lender converted $28,945 in principal and $1,902 in accrued interest into 69,039,300 common shares, leaving a remaining principal balance of $29,055. As of September 30, 2017 the accrued interest balance is $2,869. The Company is in default on this note.

F-12

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 8 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest balance is $2,420. The Company is in default on this note.

On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest balance is $5,695. The Company is in default on this note.

On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $335,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, at a conversion price equal to 60% of the lowest trading price during the 10-day period prior to conversion. As of September 30, 2017, the accrued interest is $23,310, and the OID balance is $0.

On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $563,028 which is partially funded, the current balance consolidates unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016; June 23, 2016; July 7, 2016; October 20, 2016; November 17, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. During the period ended March 31, 2017 the lender converted $34,370 in principal and $1,124 in accrued interest into 29,775,000 shares of common stock. During the period ended September 30, 2017 the lender converted $86,857 in principal and $3,048 in accrued interest into 179,650,000 common shares, leaving a principal balance of $122,086. As of September 30, 2017, the accrued interest is $3,297.

On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest is $727.

On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. This loan incurred default penalties for late filing of financial documents of $31,407 during the quarter ended September 30, 2017. The lender converted $59,799 of principle, $4,795 of interest, and $31,407 of penalties into 311,043,058 shares of common stock, leaving a loan balance of $0 as of September 30, 2017.

F-13

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 8 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. This loan incurred default penalties for late filing of financial documents of $34,156 during the quarter ended September 30, 2017. The lender converted $7,693 of principle, $18,607 of interest, and $34,156 of penalties into 219,500,000 shares of common stock, leaving a loan balance of $13,207 as of September 30, 2017. As of September 30, 2017, the accrued interest is $49.

On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or April 4, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest is $2,803.

On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or April 4, 2017, at a conversion price equal to 60% of the lowest trading price during the 10-day period prior to conversion. As of September 30, 2017, the accrued interest is $3,547, and the OID balance is $3,889.

NOTE 9 – DERIVATIVE LIABILITIES

In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date.

As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending September 30, 2017 and March 31, 2017: $29,680 note dated March 26, 2015; $60,500 note dated January 22, 2016 $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $32,000 note dated October 20, 2016; $56,000 note dated November 17, 2016; $335,000 note dated January 5, 2017; $563,028 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017; $71,457 note dated April 4, 2017; $115,000 note dated April 18, 2017.

ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item.  The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt.  During the period ended September 30, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,068,465.

F-14

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 9 – DERIVATIVE LIABILITIES (CONTINUED)

The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period.  Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0009-$0.004, exercise price of $0.0003 - $0.001, dividend yield of zero, years to maturity of 0.0137 – .5863, a risk free rate of 0.77% - 1.2%, and annualized volatility of 204% - 668%. The above loans were all discounted in full. Based on the valuations on the initial valuation dates for the period ending September 30, 2017, the Company recognized debt discounts related to the conversion features totaling $681,011 and a derivative expense of $249,457 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of September 30, 2017, unamortized debt discount, including original issue discounts totaled $174,572. The derivative liabilities totaled $1,912,905 as of September 30, 2017, of which $- related to long-term debt.

NOTE 10 – EQUITY TRANSACTIONS

The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share.

The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share.

The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model.

Date	March 30, 2017
Warrants	9,200,000
Stock price on grant date	$0.002
Exercise price	$0.002
Expected life	5 year
Volatility	120%
Risk-free rate	1.96%
Calculated value	$15,278
Fair value allocation of proceeds	$45,466

The following is a summary of the warrant activity for the period March 31, 2017 to September 30, 2017:

	Number of warrants		Weighted average exercise price
Outstanding, March 31, 2017		9,446,533	$	0.102
Granted		—		—
Exercised		—		—
Outstanding, September 30, 2017		9,446,533	$	0.102

Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

During the period ended September 30, 2017, the Company issued common stock to satisfy convertible debt conversions at a price below par value as obligated by contract. During this period the Company issued 779,232,358 common shares at a below par rate, incurring an adjustment to additional paid in capital of $502,027.

F-15

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 10 – EQUITY TRANSACTIONS (CONTINUED)

During August 2017, the Company received $100,000 from a related party as consideration for a stock subscription agreement dated October 16, 2017. The agreement stipulates issuance of 333,333,333 common stock and an additional warrants to purchase another 333,333,333 common shares at $0.0003 per share for a five year term. As of September 30, 2017, the Company has not fulfilled this obligation, thus the $100,000 collected on this agreement is recorded as common stock to be issued in the financial statements until shares are issued to complete this transaction.    

During the period ended March 31, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	488,316	$   0.00450
April 4, 2016	$4,847	862,500	$   0.00562
April 7, 2016	$1,750	486,111	$   0.00360
April 14, 2016	$4,158	962,500	$   0.00432
April 15, 2016	$1,318	488,311	$   0.00270
April 26, 2016	$1,705	631,489	$   0.00270
May 4, 2016	$2,067	485,901	$   0.00426
May 31, 2016	$   828	230,003	$   0.00360
June 2, 2016	$9,120	1,500,000	$   0.00608
June 2, 2016	$4,401	1,467,017	$   0.00300
June 14, 2016	$5,847	1,461,795	$   0.00400
June 17,2016	$5,691	1,422,808	$   0.00400
June 29, 2016	$6,580	1,063,518	$   0.00618
August 23, 2016	$2,567	1,106,487	$   0.00232
August 29, 2016	$2,570	1,107,806	$   0.00232
September 6, 2016	$2,547	1,097,634	$   0.00232
September 20, 2016	$2,443	1,263,383	$   0.00194
September 26, 2016	$2,946	1,269,672	$   0.00232
September 28, 2016	$2,947	1,270,172	$   0.00232
September 30, 2016	$3,949	2,553,336	$   0.00154
October  7, 2016	$3,381	2,914,578	$   0.00116
October  14, 2016	$3,380	2,913,784	$   0.00116
October  21, 2016	$3,385	2,917,784	$   0.00116
October  26, 2016	$3,382	2,915,828	$   0.00116
October  31, 2016	$5,037	4,341,852	$   0.00116
November  7 , 2016	$5,015	4,323,647	$   0.00116
November  22, 2016	$5,513	4,753,008	$   0.00116
November  29, 2016	$5,515	4,754,647	$   0.00116
December 6, 2016	$4,058	3,497,965	$   0.00116
January 10, 2017	$6,301	6,301,150	$   0.00100
February 22, 2017	$4,290	3,575,000	$   0.00120
March 13, 2017	$4,080	3,400,000	$   0.00120
March 21, 2017	$4,920	4,100,000	$   0.00120
March 22, 2017	$5,160	4,300,000	$   0.00120
March 24, 2017	$5,460	4,550,000	$   0.00120
March 30, 2017	$5,645	4,800,000	$   0.00118
March 31, 2017	$5,939	5,050,000	$   0.00118
March 31, 2017 Total	$150,939	90,628,002

F-16

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 10 – EQUITY TRANSACTIONS (CONTINUED)

During the period ended September 30, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 5, 2017	$6,233	5,300,000	$0.00118
April 10, 2017	$6,586	5,600,000	$0.00118
April 11, 2017	$6,880	5,850,000	$0.00118
April 18, 2017	$7,291	6,200,000	$0.00118
April 20, 2017	$7,644	6,500,000	$0.00118
April 21, 2017	$16,464	14,000,000	$0.00118
April 25, 2017	$17,287	14,700,000	$0.00118
April 26, 2017	$26,600	26,600,000	$0.00100
May 1, 2017	$8,700	14,500,000	$0.00060
June 13, 2017	$1,200	10,000,000	$0.00012
June 16, 2017	$1,930	19,299,400	$0.00010
June 16, 2017	$1,300	11,000,000	$0.00012
June 20, 2017	$1,392	11,600,000	$0.00012
June 21, 2017	$2,314	23,139,900	$0.00010
June 22, 2017	$1,590	13,250,000	$0.00012
June 22, 2017	$1,470	12,250,000	$0.00012
June 26, 2017	$1,800	15,000,000	$0.00012
June 29, 2017	$1,980	16,500,000	$0.00012
July 3, 2017	$2,088	17,400,000	$0.00012
July 12, 2017	$2,088	17,400,000	$0.00012
July 13, 2017	$2,484	13,800,000	$0.00018
July 14, 2017	$3,374	19,000,000	$0.00018
July 18, 2017	$3,374	19,000,000	$0.00018
July 20, 2017	$3,582	19,900,000	$0.00018
July 24, 2017	$6,270	20,900,000	$0.0003
July 25, 2017	$6,870	22,900,000	$0.0003
July 28, 2017	$7,200	24,000,000	$0.0003
August 2, 2017	$7,200	24,000,000	$0.0003
August 4, 2017	$9,000	25,000,000	$0.00036
August 8, 2017	$11,119	26,475,000	$0.00042
August 11, 2017	$13,920	29,000,000	$0.00048
August 16, 2017	$12,810	30,500,000	$0.00042
August 22, 2017	$6,709	19,168,058	$0.00035
August 25, 2017	$11,200	32,000,000	$0.00035
August 31, 2017	$9,600	32,000,000	$0.0003
September 7, 2017	$9,900	36,000,000	$0.00028
September 15, 2017	$9,437	37,900,000	$0.00025
September 22, 2017	$9,910	39,800,000	$0.00025
September 28, 2017	$10,408	41,800,000	$0.00025
September 30, 2017 Total	$277,204	779,232,358

F-17

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 10 – EQUITY TRANSACTIONS (CONTINUED)

(2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods.

The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model.

Date	April 6, 2015	June 9, 2015	December 15, 2015	March 30, 2017
Options	102,000	50,000	43,000	29,000,000
Stock price grant date	$1.60	$0.40	$0.20	$0.002
Initial Exercise price	$1.60	$0.40	$0.20	$0.002
Modified Exercise price	$0.20	$0.20	$0.20	-
Expected life	5.0	5.0	5.0	5.0
Volatility	99%	99%	84%	120%
Risk-free rate	1.31%	1.74%	1.70%	1.93%
Calculated value	$120,778	$14,838	$5,736	$48,017
Modified value	$151,221	$16,347	$5,736	$48,017

The following is a summary of the option activity for the period March 31, 2017 through September 30, 2017:

	Number of options		Weighted average exercise price
Outstanding, March 31, 2017		29,228,627	$	0.004
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding, September 30, 2017		29,228,627	$	0.004

The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values

F-18

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 10 – EQUITY TRANSACTIONS (CONTINUED)

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

NOTE 11 – COMMITMENTS AND CONTINGENCIES

The Company leases office space on a verbal month-to-month agreement. Monthly rent is about $2,800.

On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses.

The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

On April 1, 2017, the Company entered into a tentative agreement with CannCodex to issue 78,000,000 common shares of stock in exchange for data base assets of CannCodex. However, this agreement was not finalized and subsequently the Company is not responsible for issuance of the stock. Unrelated to this agreement, the Company has issued short-term loans to CannCodex totaling $15,300 as of September 30, 2017.

NOTE 12 – LIQUIDITY AND GOING CONCERN

The Company has a working capital deficit, has not yet received significant revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the date that these financial statements were issued. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

F-19

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2017

NOTE 13 – SUBSEQUENT EVENTS

On November 3, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $34,500. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $1,500 to cover transaction costs, the note must be repaid by August 3, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or November 3, 2017, at a conversion price equal to 60% of the lowest trading price during the 10-day period prior to conversion.

On November 13, 2017, the Company entered into a consulting agreement for drug development services which calls for a fixed cost of $7,000 as work is completed and invoiced over the one year term of the agreement.

On December 1, 2017, the Company extended the CEO’s employment agreement through November 2018.

Subsequent to the period ended September 30, 2017  , the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
October 3, 2017	$10,931	43,900,000	$0.000249
October 5, 2017	$7,582	30,448,193	$0.000249
Subsequent Total	$18,513	74,348,193

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

F-20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Company Overview  

Results of Operations for the Three and Six Months Ended September 30, 2017

We generated $115,000 in revenue for the three and six months ended September 30, 2017. We do not anticipate earning additional revenues until we are able to sell or license our products.

Our operating expenses and net income/(loss) during the three months ended September 30, 2017 were $313,463 and $1,796,247 respectively, as compared with $182,795 and ($266,519)for the same period ended 2016. Our operating expenses and net income/(loss) during the six months ended September 30, 2017 were $802,938 and ($505,637) respectively, as compared with $398,272 and ($444,883) for the same period ended 2016. The operating expenses for the three months ended September 30, 2017 consisted mainly of professional fees ($39,942), wages and taxes ($139,963), office expense ($31,828) and consulting fees ($95,375). The operating expenses for the six months ended September 30, 2017 consisted mainly of professional fees ($104,699), wages and taxes ($277,752), office expense ($98,231), consulting fees ($100,000) and research and development costs ($148,406).

We anticipate our operating expenses will continue to increase with our plan of operations.

Liquidity and Capital Resources

As of September 30, 2017, we had total current assets of $40,274; we had total current liabilities of $5,363,244; and we had a stockholders’ deficit of $5,306,432. Operating activities used $293,893 in cash for the six months ended September 30, 2017.

Our net loss of $505,637 for the six months ended September 30, 2017 primarily accounted for our negative operating cash flow. Financing activities during the six months ended September 30, 2017 generated $298,264 in cash.

As of September 30, 2017 and the date of this report, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. Our continuation as a going concern is dependent upon our ability to obtain additional financing and to generate profits and positive cash flow. We will require additional cash of $2,000,000 over the next twelve months to cover the costs of overhead and operations, drug manufacturing, maintaining our patent portfolio, and conducting clinical trials for the indication Acute Myeloid Leukemia (“AML”). We intend to raise the required capital pursuant to private debt or equity financings in the near term, but there is no guarantee or assurances that we will be able to do so. 

Off Balance Sheet Arrangements

As of September 30, 2017, there were no off balance sheet arrangements.

Going Concern

We have negative working capital and only received nominal, one-time revenue from making our technology available to a related party, we have not yet received revenues from sales of products or services  . These factors create substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern.

Our ability to continue as a going concern is dependent on generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling our equity securities and obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance we will be successful in these efforts.

4

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2017. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2017, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2017, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

We plan to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we were not been able to remediate the material weaknesses identified above. To remediate such weaknesses, and subject to our ability to obtain additional funding, we plan to implement the following changes during our fiscal year ending March 31, 2018: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting during the period ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

5

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A: Risk Factors. An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this quarterly report on Form 10Q, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. You should read the above section entitled "Forward-Looking Statements" for a discussion of what types of statements are forward-looking statements as well as the significance of such statements in the context of this report.

Risks Related To Our Business

We are a development stage company and may never commercialize any of our products or services or earn a profit. Prior to July 19, 2013, we were a “shell” company with no or nominal operations. We recently became funded and commenced operations. We are a development stage company in the business of developing treatments for Acute Myelogenous Leukemia (AML). We currently have no products ready for commercialization, have not generated any revenue from operations and expect to incur substantial net losses for the foreseeable future to further develop and commercialize our technology. We cannot predict the extent of these future net losses, or when we may attain profitability, if at all. If we are unable to generate significant revenue from our technology or attain profitability, we will not be able to sustain operations. Because of the numerous risks and uncertainties associated with developing and commercializing our technology, we are unable to predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable and you may never receive a return on an investment in our common stock. An investor in our common stock must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of medical treatments. We may never successfully commercialize our technology, and our business may fail.

We will need to raise substantial additional capital to commercialize our technology, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts. As of the date of this Annual Report on Form 10K, we have limited cash resources. Due to our expectation that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development and commercialization of our technology. During the next 12 months and potentially thereafter, we will have to raise additional funds to continue the development and commercialization of our technology. When we seek additional capital, we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which we may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of our technologies, restrict our operations or obtain funds by entering into agreements on unattractive terms.

Our ability to successfully commercialize our technology will depend largely upon the extent to which third-party payors reimburse the costs for our treatment in the future. Physicians and patients may decide not to order our products unless third-party payors, such as managed care organizations as well as government payors such as Medicare and Medicaid pay a substantial portion of the price of the treatment. Reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that our product candidates are:

• not experimental or investigational;

• effective;

• medically necessary;

• appropriate for the specific patient;

• cost-effective;

• supported by peer-reviewed publications; and

• included in clinical practice guidelines.

6

Market acceptance, sales of products based upon our technology, and our profitability may depend on reimbursement policies and health care reform measures. Several entities conduct technology assessments of medical treatments and provide the results of their assessments for informational purposes to other parties. These assessments may be used by third-party payors and health care providers as grounds to deny coverage for a treatment or procedure. The levels at which government authorities and third-party payors, such as private health insurers and health maintenance organizations, may reimburse the price patients pay for such products could affect whether we are able to commercialize our products. Our technology may receive negative assessments that may impact our ability to receive reimbursement of the treatment. Since each payor makes its own decision as to whether to establish a policy to reimburse a treatment, seeking these approvals may be a time-consuming and costly process. We cannot be sure that reimbursement in the U.S. or elsewhere will be available for any of our products in the future. If reimbursement is not available or is limited, we may not be able to commercialize our products.

If we are unable to obtain reimbursement approval from private payors and Medicare and Medicaid programs for our product candidates, or if the amount reimbursed is inadequate, our ability to generate revenues could be limited. Even if we are being reimbursed, insurers may withdraw their coverage policies or cancel their contracts with us at any time, stop paying for our treatment or reduce the payment rate for our treatment, which would reduce our revenue.

The commercial success of our product candidates will depend upon the degree of market acceptance of these products among physicians, patients, health care payors and the medical community. The use of our treatment technology has never been commercialized for any indication. Even if approved for sale by the appropriate regulatory authorities, physicians may not order treatment based upon out technology, in which event we may be unable to generate significant revenue or become profitable. Acceptance of our technology will depend on a number of factors including:

• acceptance of products based upon our technology by physicians and patients;

• successful integration into clinical practice;

• adequate reimbursement by third parties;

• cost effectiveness;

• potential advantages over alternative treatments; and

• relative convenience and ease of administration.

We will need to make leading physicians aware of the benefits of using our technology through published papers, presentations at scientific conferences and favorable results from our clinical studies. In addition, we will need to gain support from thought leaders who believe that our treatment will provide superior results. Ideally, we will need these individuals to publish support papers and articles which will be necessary to gain acceptance of our products. There is no guarantee that we will be able to obtain this support. Our failure to be successful in these efforts would make it difficult for us to convince medical practitioners to order our treatment for their patients and consequently our revenue and profitability will be limited.

If our potential treatments are unable to compete effectively with current and future treatments targeting similar markets as our potential products, our commercial opportunities will be reduced or eliminated. The medical treatment industry for AML and stroke is intensely competitive and characterized by rapid technological progress. In each of our potential product areas, we face significant competition from large biotechnology, medical diagnostic and other companies. The technologies associated with the medical industry are evolving rapidly and there is intense competition within such industry. Certain companies have established technologies that may be competitive to our technology and any future products that we develop. Some of these competing companies may use different approaches or means to obtain results, which could be more effective or less expensive than our treatments. Moreover, these and other future competitors have or may have considerably greater resources than we do in terms of technology, sales, marketing, commercialization and capital resources. These competitors may have substantial advantages over us in terms of research and development expertise, experience in clinical studies, experience in regulatory issues, brand name exposure and expertise in sales and marketing as well as in operating central laboratory services. Many of these organizations have financial, marketing and human resources greater than ours; therefore, there can be no assurance that we can successfully compete with present or potential competitors or that such competition will not have a materially adverse effect on our business, financial position or results of operations.

Since our technology is under development, we cannot predict the relative competitive position of any product based upon the technology. However, we expect that the following factors will determine our ability to compete effectively: safety and efficacy; product price; turnaround time; ease of administration; performance; reimbursement; and marketing and sales capability.

7

If our clinical studies do not prove the superiority of our technologies, we may never sell our products and services. The results of our clinical studies may not show that treatment results using our technology are superior to existing treatment. In that event, we will have to devote significant financial and other resources to further research and development, and commercialization of products using our technologies will be delayed or may never occur.

If we do not receive regulatory approvals, we may not be able to develop and commercialize our technology. We will need FDA approval to market products based on our technology in the United States and approvals from foreign regulatory authorities to market products based on our technology outside the United States. We have not yet filed an application with the FDA to obtain approval to market any of our proposed products. If we fail to obtain regulatory approval for the marketing of products based on our technology, we will be unable to sell such products and will not be able to sustain operations. The regulatory review and approval process, which may include evaluation of preclinical studies and clinical trials of products based on our technology, as well as the evaluation of manufacturing processes and contract manufacturers’ facilities, is lengthy, expensive and uncertain. Securing regulatory approval for products based upon our technology may require the submission of extensive preclinical and clinical data and supporting information to regulatory authorities to establish such products’ safety and effectiveness for each indication. We have limited experience in filing and pursuing applications necessary to gain regulatory approvals.

Regulatory authorities generally have substantial discretion in the approval process and may either refuse to accept an application, or may decide after review of an application that the data submitted is insufficient to allow approval of any product based upon our technology. If regulatory authorities do not accept or approve our applications, they may require that we conduct additional clinical, preclinical or manufacturing studies and submit that data before regulatory authorities will reconsider such application. We may need to expend substantial resources to conduct further studies to obtain data that regulatory authorities believe is sufficient. Depending on the extent of these studies, approval of applications may be delayed by several years, or may require us to expend more resources than we may have available. It is also possible that additional studies may not suffice to make applications approvable. If any of these outcomes occur, we may be forced to abandon our applications for approval, which might cause us to cease operations.

If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage. We will rely on patent protection as well as a combination of copyright and trade secret protection, and other contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies and they will be able to compete more effectively against us. We cannot assure you that the patent issued to us will not be challenged, invalidated or held unenforceable. We cannot guarantee you that we will be successful in defending challenges made in connection with our patent and any future patent applications. In addition to our patent and any future patent applications, we will rely on contractual restrictions to protect our proprietary technology. We will require our employees and third parties to sign confidentiality agreements and employees to also sign agreements assigning to us all intellectual property arising from their work for us. Nevertheless, we cannot guarantee that these measures will be effective in protecting our intellectual property rights. 

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our technology. The inventor of the intellectual property which was assigned to the Company in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial unpaid legal fees in defending the Litigation and any collection action against the Company for those unpaid legal fees could result in a judgment against the Company and the foreclosure upon all of our assets which would have a material adverse effect on the Company and the price of its shares.

Also, our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies. There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our products or processes. If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the United States Patent and Trademark Office to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions. In addition, we cannot assure you that we would prevail in any of these suits or that the damages or other remedies if any, awarded against us would not be substantial. Claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties that may not be available on acceptable terms, if at all. We may also become subject to injunctions against the further development and use of our technology, which would have a material adverse effect on our business, financial condition and results of operations. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

8

Our financial statements have been prepared assuming that the Company will continue as a going concern. We have generated losses to date and have limited working capital. These factors raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from this uncertainty. The report of our independent registered public accounting firm included an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern in their audit report included herein. If we cannot generate the required revenues and gross margin to achieve profitability or obtain additional capital on acceptable terms, we will need to substantially revise our business plan or cease operations and an investor could suffer the loss of a significant portion or all of his investment in our Company.

We do not expect to pay dividends for the foreseeable future, and we may never pay dividends and, consequently, the only opportunity for investors to achieve a return on their investment is if a trading market develops and investors are able to sell their shares for a profit or if our business is sold at a price that enables investors to recognize a profit.   We currently intend to retain any future earnings to support the development and expansion of our business and do not anticipate paying cash dividends for the foreseeable future. Our payment of any future dividends will be at the discretion of our Board of Directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. In addition, our ability to pay dividends on our common stock may be limited by state law. Accordingly, we cannot assure investors any return on their investment, other than in connection with a sale of their shares or a sale of our business. At the present time there is a limited trading market for our shares. Therefore, holders of our securities may be unable to sell them. We cannot assure investors that an active trading market will develop or that any third party will offer to purchase our business on acceptable terms and at a price that would enable our investors to recognize a profit.

Corporate and Other Risks

Limitations on director and officer liability and indemnification of our Company’s officers and directors by us may discourage stockholders from bringing suit against an officer or director.  Our Company’s certificate of incorporation and bylaws provide, with certain exceptions as permitted by governing state law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a director, except for acts or omissions which involve intentional misconduct, fraud or knowing violation of law, or unlawful payments of dividends. These provisions may discourage stockholders from bringing suit against a director for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on our behalf against a director.

We are responsible for the indemnification of our officers and directors. Should our officers and/or directors require us to contribute to their defense, we may be required to spend significant amounts of our capital. Our certificate of incorporation and bylaws also provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney's fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of our Company. This indemnification policy could result in substantial expenditures, which we may be unable to recoup. If these expenditures are significant, or involve issues which result in significant liability for our key personnel, we may be unable to continue operating as a going concern.

Certain provisions of our Certificate of Incorporation may make it more difficult for a third party to effect a change-of-control. Our certificate of incorporation authorizes the Board of Directors to issue up to 10,000,000 shares of preferred stock. The preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by the Board of Directors without further action by the stockholders. These terms may include preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The issuance of any preferred stock could diminish the rights of holders of our common stock, and therefore could reduce the value of such common stock. In addition, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell assets to, a third party. The ability of the Board of Directors to issue preferred stock could make it more difficult, delay, discourage, prevent or make it more costly to acquire or effect a change-in-control, which in turn could prevent our stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock.

9

The issuance of Preferred Stock to our Chief Executive Officer provides him with voting control which may limit your ability and the ability of our other stockholders, whether acting alone or together, to propose or direct the management or overall direction of our Company. Our Chief Executive Officer has 6,000,000 shares of Preferred Stock which provide him with 1000 to 1 voting rights over shares of common stock. This ownership provides him with voting control over matters which require shareholder approval. This concentration of voting power could discourage or prevent a potential takeover of our Company that might otherwise result in an investor receiving a premium over the market price for his shares. If you acquire shares of our common stock, you may have no effective voice in the management of our Company.  Such concentrated control of our Company may adversely affect the price of our common stock. Our principal stockholders may be able to control matters requiring approval by our stockholders, including the election of directors, mergers or other business combinations. Such concentrated control may also make it difficult for our stockholders to receive a premium for their shares of our common stock in the event we merge with a third party or enter into different transactions which require stockholder approval. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock. 

We are dependent for our success on a few key individuals.  Our success depends on the skills, experience and performance of key members of our management team.  Each of those individuals may voluntarily terminate his relationship with the Company at any time. Were we to lose one or more of these key individuals, we would be forced to expend significant time and money in the pursuit of a replacement, which would result in both a delay in the implementation of our business plan and the diversion of limited working capital. We do not maintain a key man insurance policy on any of our executive officers.

Capital Market Risks

Our common stock recently commenced trading and has limited volume and high price volatility, so you may be unable to sell your shares to raise money or otherwise desire to liquidate your shares.  The Company’s common stock commenced trading March 14, 2014 on the OTC Markets. The trading volume has been very limited by the fact that many major institutional investment funds, including mutual funds, as well as individual investors follow a policy of not investing in OTC stocks and certain major brokerage firms restrict their brokers from recommending OTC stocks because they are considered speculative, volatile, thinly traded and the market price of the common stock may not accurately reflect our underlying value. The market price of our common stock is subject to wide fluctuations, and may be subject to further fluctuations based on announcements of new products or services by us, significant sales of our common stock, including “short” sales, the operating and stock price performance of other companies that investors may deem comparable to us, and news reports relating to trends in our markets or general economic conditions.

The application of the “penny stock” rules to our common stock could limit the trading and liquidity of the common stock, adversely affect the market price of our common stock and increase your transaction costs to sell those shares. As long as the trading price of our common stock is below $5 per share, the open-market trading of our common stock will be subject to the “penny stock” rules, unless we otherwise qualify for an exemption from the “penny stock” definition. The “penny stock” rules impose additional sales practice requirements on certain broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). These regulations, if they apply, require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. Under these regulations, certain brokers who recommend such securities to persons other than established customers or certain accredited investors must make a special written suitability determination regarding such a purchaser and receive such purchaser’s written agreement to a transaction prior to sale. These regulations may have the effect of limiting the trading activity of our common stock, reducing the liquidity of an investment in our common stock and increasing the transaction costs for sales and purchases of our common stock as compared to other securities. The stock market in general and the market prices for penny stock companies in particular, have experienced volatility that often has been unrelated to the operating performance of such companies. These broad market and industry fluctuations may adversely affect the price of our stock, regardless of our operating performance.  Stockholders should be aware that, according to Securities and Exchange Commission (“SEC”) Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include 1) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; 2) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; 3) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; 4) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and 5) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. The occurrence of these patterns or practices could increase the volatility of our share price.

We may not be able to attract the attention of major brokerage firms, which could have a material adverse impact on the market value of our common stock.  Security analysts of major brokerage firms may not provide coverage of our common stock since there is no incentive to brokerage firms to recommend the purchase of our common stock. The absence of such coverage limits the likelihood that an active market will develop for our common stock. It will also likely make it more difficult to attract new investors at times when we require additional capital.

We may be unable to list our common stock on NASDAQ or on any securities exchange. Although we may apply to list our common stock on NASDAQ or the American Stock Exchange in the future, we cannot assure you that we will be able to meet the initial listing standards, including the minimum per share price and minimum capitalization requirements, or that we will be able to maintain a listing of our common stock on either of those or any other trading venue. If our common stock begins trading, until such time as we would qualify for listing on NASDAQ, the American Stock Exchange or another trading venue, our common stock would trade on OTC Markets or OTC Bulletin Board or another over-the-counter quotation system where an investor may find it more difficult to dispose of shares or obtain accurate quotations as to the market value of our common stock. In addition, rules promulgated by the SEC impose various practice requirements on broker-dealers who sell securities that fail to meet certain criteria set forth in those rules to persons other than established customers and accredited investors.  Consequently, if our common stock begins trading, these rules may deter broker-dealers from recommending or selling our common stock, which may further affect the liquidity of our common stock. It would also make it more difficult for us to raise additional capital.

10

Future sales and issuances of our equity securities could put downward selling pressure on our securities, and adversely affect the stock price. There is a risk that this downward pressure may make it impossible for an investor to sell his or her securities at any reasonable price, if at all. Future sales of substantial amounts of our equity securities in the public market, or the perception that such sales could occur, could put downward selling pressure on our securities, and adversely affect the market price of our common stock.

Conversion of our convertible notes into common stock could result in additional dilution to our stockholders. We have issued convertible notes which are convertible into shares of our common stock at conversion prices which are at a discount to the then current trading price of our common stock. Additionally, upon the occurrence of certain events of default (including conditions outside of our control) the note holders are entitled to increased repayment and interest rates, as well as other remedies. The note holders have anti-dilution and conversion reset provisions which are triggered by the issuance of lower priced securities. The Company has issued a significant number of shares of common stock as a result of the conversion of these convertible notes and expects to continue to issue a significant number of shares in the future. A significant portion of these additional share issuances resulted from the conversion of convertible notes. As shares of our common stock are issued due to the conversion of some or all of the convertible notes in the future, the ownership interests of existing stockholders will continue to be diluted and such dilution is expected to be significant.

Events of Default under our convertible notes could result in a judgment against the Company and a foreclosure on all of our assets. We have issued convertible notes which have remedies to the note holder which include a confession of judgment against us in the event of a default. We are currently in default under these convertible notes for our failure to timely file our public reports with the Securities and Exchange Commission. The exercise of rights by the note holder for this event of default could result in a judgment against us and the foreclosure upon all of our assets which would have a material adverse effect on the Company and the price of its shares.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

An “Event of Default” has occurred under the terms of each of the Company’s previously disclosed convertible promissory notes issued to GHS Investments LLC because the Company has not remained current in its timely filings of this Form 10Q with the Securities and Exchange Commission. These Events of Default have resulted in the increase of principal of $65,957.91. 

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 formatted in Extensible Business Reporting Language (XBRL).

**Provided herewith

11

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Rich Pharmaceuticals, Inc.
Date:	December 29, 2017
	By: /s/ Ben Chang Ben Chang Title: Chief Executive Officer and Director

12

EX-31.1

CERTIFICATIONS

I, Ben Chang, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2017 of Rich Pharmaceuticals, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 29, 2017

/s/ Ben Chang

By: Ben Chang

Title: Chief Executive Officer

EX-31.2

CERTIFICATIONS

I, Ben Chang, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2017 of Rich Pharmaceuticals, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 29, 2017

/s/ Ben Chang

By: Ben Chang

Title: Chief Financial Officer

EX-32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of Rich Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission (the “Report”), I, Ben Chang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Ben Chang
Name:	Ben Chang
Title:	Principal Executive Officer, Principal Financial Officer and Director
Date:	December 29, 2017

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

XML

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2017	Dec. 29, 2017
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	0001504389
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		955,027,821
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018

XML

Balance Sheets - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Current Assets
Cash and equivalents	$ 24,974	$ 40,903
Notes receivable	15,300	10,000
Total Current Assets	40,274	50,903
Property and equipment, net	1,538	2,125
Securities available for sale	15,000
TOTAL ASSETS	56,812	53,028
Current Liabilities
Accounts payable	312,134	296,635
Accounts payable related party	286,700	53,000
Accrued expenses	1,188,520	937,783
Due to related parties	54,001	49,395
Note payable	920,000	920,000
Convertible notes payable, net of debt discount of $174,572 and $356,819	688,984	514,075
Derivative liabilities	1,912,905	2,607,959
Total Current Liabilities	5,363,244	5,378,847
Long-term Liabilities
Convertible notes payable, net of debt discount
Derivative liabilities
Total Long-term Liabilities
Total Liabilities	5,363,244	5,378,847
Commitments and Contingencies
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 880,678,573 and 101,446,215 shares issued and outstanding,	880,678	101,446
Common stock to be issued	100,000
Additional paid-in capital	6,657,296	7,011,504
Accumulated deficit	(12,950,406)	(12,444,769)
Total Stockholders Deficit	(5,306,432)	(5,325,819)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 56,812	$ 53,028

XML

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ .001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Issued	880,678,573	101,446,215
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000
Convertible notes payable, debt discount	$ 174,572	$ 356,819

XML

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
REVENUES	$ 115,000		$ 115,000
OPERATING EXPENSES
Consulting expenses	95,375	5,850	100,000	16,075
Office expenses	31,828	35,472	98,231	70,046
Depreciation expense	313	431	586	863
Wages and taxes	139,963	96,001	277,752	191,956
Professional fees	39,942	34,158	104,699	88,401
Regulatory fees	4,182	2,686	38,491	9,529
Research and development	833		148,406
Stock-based compensation
Travel, meals and entertainment	19,027	8,197	34,773	21,403
TOTAL OPERATING EXPENSES	331,463	182,795	802,938	398,272
LOSS FROM OPERATIONS	(216,463)	(182,795)	(687,938)	(398,272)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(330,681)	(25,786)	(681,011)	(72,360)
Change in value of derivative liability	2,465,455	51,683	1,068,465	168,454
Derivative expense			(249,457)
Interest expense	(121,909)	(109,466)	(168,682)	(142,475)
Interest expense related party	(155)	(155)	(308)	(230)
Gain (Loss) on extinguishment of debt			213,294
TOTAL OTHER INCOME EXPENSES	2,012,710	(83,724)	182,301	(46,611)
INCOME/(LOSS) BEFORE PROVISION FOR INCOME TAXES	1,796,247	(266,519)	(505,637)	(444,883)
PROVISION FOR INCOME TAXES
NET INCOME/(LOSS)	$ 1,796,247	$ (266,519)	$ (505,637)	$ (444,883)
NET INCOME/(LOSS) PER SHARE: BASIC AND DILUTED	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	602,711,661	23,050,307	397,523,663	19,935,954

XML

Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ 1,796,247	$ (266,519)	$ (505,637)	$ (444,883)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	313	431	586	863	$ 1,606
Amortization of debt discount	330,681	25,786	681,011	72,360
Change in value of derivative liability	(2,465,455)	(51,683)	(1,068,465)	(168,454)
Derivative expense			249,457
Gain on extinguishment of debt			(213,294)
Warrants issued for services
Stock-based compensation
Changes in operating assets and liabilities:
Decrease in prepaid expenses				2,800
Increase (decrease) in bank overdraft				(800)
Increase in accounts payable			249,199	111,299
Increase in accrued expenses			313,250	236,377
Net Cash Used by Operating Activities			(293,893)	(190,438)
CASH FLOWS FROM INVESTING ACTIVITY:
Increase in notes receivable			(5,300)
Increase in stock held for investment			(15,000)
Net Cash Used by Investing Activities			(20,300)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties			4,606	(37,812)
Proceeds from sale of common stock and warrants			100,000
Proceeds from issuance of note payable
Proceeds from issuance of convertible notes payable			193,658	228,250
Net Cash Provided by Financing Activities			298,264	190,438
Net Increase (Decrease) in Cash and Cash Equivalents			(15,929)
Cash and cash equivalents, beginning of period			40,903
Cash and cash equivalents, end of period	$ 24,974		24,974		$ 40,903
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable				900,000
Warrants issued for accrued expenses
Original issue discounts recorded on notes payable			10,000
Debt discounts recorded on convertible notes payable			498,764
Debt/interest converted into common stock and contributed capital			$ 277,208	$ 70,478

XML

Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Nature of Business

On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”).

On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000.

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.)

On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2017 and March 31, 2017 the Company had $24,974 and $40,903, respectively, of unrestricted cash.

Basis of Presentation

The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.

Long-Lived and Intangible Assets

The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;

Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company did not have any level 3 financial instruments at September 30, 2017 or March 31, 2017. As of September 30, 2017, the securities available for sale were considered a level 1 item (see note 3); the derivative liabilities were considered a level 2 item (see Note 9).

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company has made all adjustments necessary for a fair presentation of the interim financial information and all such adjustments are normal and recurring in nature, as required under ASC Topic 270.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Research and Development

The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts).

Basic Loss Per Share

The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

XML

Property and equipment

6 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Property and equipment

Property and equipment, recorded at cost, consisted of the following as of September 30, 2017 and March 31, 2017:

	September 30, 2017			March 31, 2017
Computer equipment & furniture	$	5,160		$	5,160
Less: accumulated depreciation		(3,622	)		(3,035	)
Property and equipment, net	$	1,538		$	2,125

The useful life of the computer equipment and furniture is 3 years.

Depreciation expense was $586 and $1,606 for the periods ended September 30, 2017 and March 31, 2017, respectively.

XML

Securities Available For Sale

6 Months Ended

Sep. 30, 2017

Investments, Debt and Equity Securities [Abstract]

Securities Available For Sale

The Company received 15,000,000 common stock shares of an entity that is majority owned by a non-majority stockholder of the Company designating the two entities as under common control. This transaction is partial payment for access to the Company’s intellectual property. This holding represents about 11% of the ownership of the invested company. The Company classifies its equity securities held as available for sale, and as such, they are carried at fair value. Changes in fair value of available for sale securities will be reported as a component of other comprehensive income and evaluated at the end of each quarter. The shares currently do not have a firm quoted trading price and thus they are carried at their par value until such time as the shares have established a trading price in the market. It should be noted that recording this transaction at par value of the securities is the same treatment recorded by the issuing company due to the lack of active market and lack of transferability of the shares.

XML

Intangible Assets

6 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.

On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.

XML

Accrued Expenses

6 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consisted of the following as of September 30, 2017 and March 31, 2017:

	September 30, 2017		March 31, 2017
Wages and taxes	$	1,012,457	$	829,231
Accrued interest		176,063		108,552
Total accrued expenses	$	1,188,520	$	937,783

XML

Related Party Debt and Transactions

6 Months Ended

Sep. 30, 2017

Related Party Transactions [Abstract]

Related Party Debt and Transactions

During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest and has an original due date of January 8, 2016. There is a total due of $12,280 as of September 30, 2017 and March 31, 2017. Interest accrued on the note as of September 30, 2017 was $1,211. The Company is in default on the balance of this note.

During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of September 30, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company.

Periodically, related parties incur expenses for the Company and are expected to be repaid for those expenditures. As of September 30, 2017, the balance owed to related parties for these types of expenses is $40,160. These liabilities do not have stated interest rates or due dates, but are payable at the discretion of the Company.

The Company has a consulting agreement with a related party to provide research into new technologies as well as essential development of current products. The amounts owed to this related party for past work is a part of accounts payable and totals $286,700 and $53,000 for the periods ending September 30, 2017 and March 31, 2017, respectively.

On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended through November 2018; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $137,500 and $275,000 for the six months ended September 30, 2017 and the twelve months ended March 31, 2017 (respectively) as a result of this agreement, these amounts contribute to the $737,611 and $645,945 of officer compensation which is included in accrued expenses, as of September 30, 2017 and March 31, 2017.

The intangible assets (as described in note 4) were made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement accounts for all of the $115,000 of revenue recognized by the Company.

XML

Note Payable

6 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Note Payable

On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $120,082 as of September 30, 2017.

On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $969 as of September 30, 2017.

XML

Convertible Note Payable

6 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Convertible Note Payable

On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, incurring additional financing fees of $11,819. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $8,838, (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. Accrued interest was $4,602 as of September 30, 2017. The Company is in default on the balance of this note.

On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2017.

On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of March 31, 2017. On February 22, 2017, this note was purchased for a renegotiated face value of $20,900, incurring additional financing fees of $5,150. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2017 the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. As of March 31, 2017 the principal and accrued interest balance is $0.

On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $20,280, incurring additional financing fees of $1,280. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on December 29, 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $1,609. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. On April 4, 2017, this note was purchased for a renegotiated face value of $71,457. (details provided under the note dated April 4, 2017 below). As of September 30, 2017 the principal and accrued interest balance is $0.

On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on February 25, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2017 the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $10,755. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on March 24, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $7,500. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $38,107, incurring additional financing fees of $8,107. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, incurring additional financing fees of $49,964. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0.

On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017 the accrued interest balance is $5,695.

On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. During the period ended September 30, 2017, the lender converted $28,945 in principal and $1,902 in accrued interest into 69,039,300 common shares, leaving a remaining principal balance of $29,055. As of September 30, 2017 the accrued interest balance is $2,869. The Company is in default on this note.

On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest balance is $2,420. The Company is in default on this note.

On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest balance is $5,695. The Company is in default on this note.

On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $335,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, at a conversion price equal to 60% of the lowest trading price during the 10-day period prior to conversion. As of September 30, 2017, the accrued interest is $23,310, and the OID balance is $0.

On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $563,028 which is partially funded, the current balance consolidates unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016; June 23, 2016; July 7, 2016; October 20, 2016; November 17, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. During the period ended March 31, 2017 the lender converted $34,370 in principal and $1,124 in accrued interest into 29,775,000 shares of common stock. During the period ended September 30, 2017 the lender converted $86,857 in principal and $3,048 in accrued interest into 179,650,000 common shares, leaving a principal balance of $122,086. As of September 30, 2017, the accrued interest is $3,297.

On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest is $727.

On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. This loan incurred default penalties for late filing of financial documents of $31,407 during the quarter ended September 30, 2017. The lender converted $59,799 of principle, $4,795 of interest, and $31,407 of penalties into 311,043,058 shares of common stock, leaving a loan balance of $0 as of September 30, 2017.

On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. This loan incurred default penalties for late filing of financial documents of $34,156 during the quarter ended September 30, 2017. The lender converted $7,693 of principle, $18,607 of interest, and $34,156 of penalties into 219,500,000 shares of common stock, leaving a loan balance of $13,207 as of September 30, 2017. As of September 30, 2017, the accrued interest is $49.

On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or April 4, 2017, at a conversion price equal to 60% of the lowest trading price during the 20-day period prior to conversion. As of September 30, 2017, the accrued interest is $2,803.

On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or April 4, 2017, at a conversion price equal to 60% of the lowest trading price during the 10-day period prior to conversion. As of September 30, 2017, the accrued interest is $3,547, and the OID balance is $3,889.

XML

Derivative Liabilities

6 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Derivative Liabilities

In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date.

As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending September 30, 2017 and March 31, 2017: $29,680 note dated March 26, 2015; $60,500 note dated January 22, 2016 $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $32,000 note dated October 20, 2016; $56,000 note dated November 17, 2016; $335,000 note dated January 5, 2017; $563,028 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017; $71,457 note dated April 4, 2017; $115,000 note dated April 18, 2017.

ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item.  The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt.  During the period ended September 30, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,068,465.

The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period.  Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0009-$0.004, exercise price of $0.0003 - $0.001, dividend yield of zero, years to maturity of 0.0137 – .5863, a risk free rate of 0.77% - 1.2%, and annualized volatility of 204% - 668%. The above loans were all discounted in full. Based on the valuations on the initial valuation dates for the period ending September 30, 2017, the Company recognized debt discounts related to the conversion features totaling $681,011 and a derivative expense of $249,457 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of September 30, 2017, unamortized debt discount, including original issue discounts totaled $174,572. The derivative liabilities totaled $1,912,905 as of September 30, 2017, of which $- related to long-term debt.

XML

Equity Transactions

6 Months Ended

Sep. 30, 2017

Equity Transactions

Equity Transactions

The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share.

The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share.

The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model.

Date	March 30, 2017
Warrants	9,200,000
Stock price on grant date	$0.002
Exercise price	$0.002
Expected life	5 year
Volatility	120%
Risk-free rate	1.96%
Calculated value	$15,278
Fair value allocation of proceeds	$45,466

The following is a summary of the warrant activity for the period March 31, 2017 to September 30, 2017:

	Number of warrants		Weighted average exercise price
Outstanding, March 31, 2017		9,446,533	$	0.102
Granted		—		—
Exercised		—		—
Outstanding, September 30, 2017		9,446,533	$	0.102

Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

During the period ended September 30, 2017, the Company issued common stock to satisfy convertible debt conversions at a price below par value as obligated by contract. During this period the Company issued 779,232,358 common shares at a below par rate, incurring an adjustment to additional paid in capital of $502,027.

During August 2017, the Company received $100,000 from a related party as consideration for a stock subscription agreement dated October 16, 2017. The agreement stipulates issuance of 333,333,333 common stock and an additional warrants to purchase another 333,333,333 common shares at $0.0003 per share for a five year term. As of September 30, 2017, the Company has not fulfilled this obligation, thus the $100,000 collected on this agreement is recorded as common stock to be issued in the financial statements until shares are issued to complete this transaction.    

During the period ended March 31, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	488,316	$   0.00450
April 4, 2016	$4,847	862,500	$   0.00562
April 7, 2016	$1,750	486,111	$   0.00360
April 14, 2016	$4,158	962,500	$   0.00432
April 15, 2016	$1,318	488,311	$   0.00270
April 26, 2016	$1,705	631,489	$   0.00270
May 4, 2016	$2,067	485,901	$   0.00426
May 31, 2016	$   828	230,003	$   0.00360
June 2, 2016	$9,120	1,500,000	$   0.00608
June 2, 2016	$4,401	1,467,017	$   0.00300
June 14, 2016	$5,847	1,461,795	$   0.00400
June 17,2016	$5,691	1,422,808	$   0.00400
June 29, 2016	$6,580	1,063,518	$   0.00618
August 23, 2016	$2,567	1,106,487	$   0.00232
August 29, 2016	$2,570	1,107,806	$   0.00232
September 6, 2016	$2,547	1,097,634	$   0.00232
September 20, 2016	$2,443	1,263,383	$   0.00194
September 26, 2016	$2,946	1,269,672	$   0.00232
September 28, 2016	$2,947	1,270,172	$   0.00232
September 30, 2016	$3,949	2,553,336	$   0.00154
October  7, 2016	$3,381	2,914,578	$   0.00116
October  14, 2016	$3,380	2,913,784	$   0.00116
October  21, 2016	$3,385	2,917,784	$   0.00116
October  26, 2016	$3,382	2,915,828	$   0.00116
October  31, 2016	$5,037	4,341,852	$   0.00116
November  7 , 2016	$5,015	4,323,647	$   0.00116
November  22, 2016	$5,513	4,753,008	$   0.00116
November  29, 2016	$5,515	4,754,647	$   0.00116
December 6, 2016	$4,058	3,497,965	$   0.00116
January 10, 2017	$6,301	6,301,150	$   0.00100
February 22, 2017	$4,290	3,575,000	$   0.00120
March 13, 2017	$4,080	3,400,000	$   0.00120
March 21, 2017	$4,920	4,100,000	$   0.00120
March 22, 2017	$5,160	4,300,000	$   0.00120
March 24, 2017	$5,460	4,550,000	$   0.00120
March 30, 2017	$5,645	4,800,000	$   0.00118
March 31, 2017	$5,939	5,050,000	$   0.00118
March 31, 2017 Total	$150,939	90,628,002

During the period ended September 30, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 5, 2017	$6,233	5,300,000	$0.00118
April 10, 2017	$6,586	5,600,000	$0.00118
April 11, 2017	$6,880	5,850,000	$0.00118
April 18, 2017	$7,291	6,200,000	$0.00118
April 20, 2017	$7,644	6,500,000	$0.00118
April 21, 2017	$16,464	14,000,000	$0.00118
April 25, 2017	$17,287	14,700,000	$0.00118
April 26, 2017	$26,600	26,600,000	$0.00100
May 1, 2017	$8,700	14,500,000	$0.00060
June 13, 2017	$1,200	10,000,000	$0.00012
June 16, 2017	$1,930	19,299,400	$0.00010
June 16, 2017	$1,300	11,000,000	$0.00012
June 20, 2017	$1,392	11,600,000	$0.00012
June 21, 2017	$2,314	23,139,900	$0.00010
June 22, 2017	$1,590	13,250,000	$0.00012
June 22, 2017	$1,470	12,250,000	$0.00012
June 26, 2017	$1,800	15,000,000	$0.00012
June 29, 2017	$1,980	16,500,000	$0.00012
July 3, 2017	$2,088	17,400,000	$0.00012
July 12, 2017	$2,088	17,400,000	$0.00012
July 13, 2017	$2,484	13,800,000	$0.00018
July 14, 2017	$3,374	19,000,000	$0.00018
July 18, 2017	$3,374	19,000,000	$0.00018
July 20, 2017	$3,582	19,900,000	$0.00018
July 24, 2017	$6,270	20,900,000	$0.0003
July 25, 2017	$6,870	22,900,000	$0.0003
July 28, 2017	$7,200	24,000,000	$0.0003
August 2, 2017	$7,200	24,000,000	$0.0003
August 4, 2017	$9,000	25,000,000	$0.00036
August 8, 2017	$11,119	26,475,000	$0.00042
August 11, 2017	$13,920	29,000,000	$0.00048
August 16, 2017	$12,810	30,500,000	$0.00042
August 22, 2017	$6,709	19,168,058	$0.00035
August 25, 2017	$11,200	32,000,000	$0.00035
August 31, 2017	$9,600	32,000,000	$0.0003
September 7, 2017	$9,900	36,000,000	$0.00028
September 15, 2017	$9,437	37,900,000	$0.00025
September 22, 2017	$9,910	39,800,000	$0.00025
September 28, 2017	$10,408	41,800,000	$0.00025
September 30, 2017 Total	$277,204	779,232,358

(2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods.

The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model.

Date	April 6, 2015	June 9, 2015	December 15, 2015	March 30, 2017
Options	102,000	50,000	43,000	29,000,000
Stock price grant date	$1.60	$0.40	$0.20	$0.002
Initial Exercise price	$1.60	$0.40	$0.20	$0.002
Modified Exercise price	$0.20	$0.20	$0.20	-
Expected life	5.0	5.0	5.0	5.0
Volatility	99%	99%	84%	120%
Risk-free rate	1.31%	1.74%	1.70%	1.93%
Calculated value	$120,778	$14,838	$5,736	$48,017
Modified value	$151,221	$16,347	$5,736	$48,017

The following is a summary of the option activity for the period March 31, 2017 through September 30, 2017:

	Number of options		Weighted average exercise price
Outstanding, March 31, 2017		29,228,627	$	0.004
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding, September 30, 2017		29,228,627	$	0.004

The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

XML

Commitments and Contigencies

6 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Commitments and Contingencies

The Company leases office space on a verbal month-to-month agreement. Monthly rent is about $2,800.

On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses.

The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

On April 1, 2017, the Company entered into a tentative agreement with CannCodex to issue 78,000,000 common shares of stock in exchange for data base assets of CannCodex. However, this agreement was not finalized and subsequently the Company is not responsible for issuance of the stock. Unrelated to this agreement, the Company has issued short-term loans to CannCodex totaling $15,300 as of September 30, 2017.

XML

Liquidity and Going Concern

6 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Going Concern

The Company has a working capital deficit, has not yet received significant revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the date that these financial statements were issued. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

XML

Subsequent Events

6 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Subsequent Events

On November 3, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $34,500. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $1,500 to cover transaction costs, the note must be repaid by August 3, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or November 3, 2017, at a conversion price equal to 60% of the lowest trading price during the 10-day period prior to conversion.

On November 13, 2017, the Company entered into a consulting agreement for drug development services which calls for a fixed cost of $7,000 as work is completed and invoiced over the one year term of the agreement.

On December 1, 2017, the Company extended the CEO’s employment agreement through November 2018.

Subsequent to the period ended September 30, 2017  , the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
October 3, 2017	$10,931	43,900,000	$0.000249
October 5, 2017	$7,582	30,448,193	$0.000249
Subsequent Total	$18,513	74,348,193

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Nature of Business

On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”).

On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000.

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.)

On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2017 and March 31, 2017 the Company had $24,974 and $40,903, respectively, of unrestricted cash.

Basis of Presentation

The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.

Long-Lived and Intangible Assets

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.

On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. This asset was made accessible to a related party as part of a support and collaboration agreement dated July 11, 2017, in exchange for payment including 15,000,000 shares of the related parties common stock and cash of $100,000. This agreement does not diminish the Company’s ability to use or benefit from this asset. See note 3.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;

Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company did not have any level 3 financial instruments at September 30, 2017 or March 31, 2017. As of September 30, 2017, the securities available for sale were considered a level 1 item (see note 3); the derivative liabilities were considered a level 2 item (see Note 9).

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company has made all adjustments necessary for a fair presentation of the interim financial information and all such adjustments are normal and recurring in nature, as required under ASC Topic 270.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Research and Development

The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts).

Basic loss per share

The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,195,000 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

XML

Property and equipment (Tables)

6 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

	September 30, 2017			March 31, 2017
Computer equipment & furniture	$	5,160		$	5,160
Less: accumulated depreciation		(3,622	)		(3,035	)
Property and equipment, net	$	1,538		$	2,125

XML

Accrued Expenses (Tables)

6 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

	September 30, 2017		March 31, 2017
Wages and taxes	$	1,012,457	$	829,231
Accrued interest		176,063		108,552
Total accrued expenses	$	1,188,520	$	937,783

XML

Equity Transactions (Tables)

1 Months Ended

6 Months Ended

12 Months Ended

Oct. 31, 2017

Sep. 30, 2017

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Value of Warrants

Date	March 30, 2017
Warrants	9,200,000
Stock price on grant date	$0.002
Exercise price	$0.002
Expected life	5 year
Volatility	120%
Risk-free rate	1.96%
Calculated value	$15,278
Fair value allocation of proceeds	$45,466

Schedule of Warrant Activity

	Number of warrants		Weighted average exercise price
Outstanding, March 31, 2017		9,446,533	$	0.102
Granted		—		—
Exercised		—		—
Outstanding, September 30, 2017		9,446,533	$	0.102

Schedule of Conversions of Common Stock

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
October 3, 2017	$10,931	43,900,000	$0.000249
October 5, 2017	$7,582	30,448,193	$0.000249
Subsequent Total	$18,513	74,348,193

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 5, 2017	$6,233	5,300,000	$0.00118
April 10, 2017	$6,586	5,600,000	$0.00118
April 11, 2017	$6,880	5,850,000	$0.00118
April 18, 2017	$7,291	6,200,000	$0.00118
April 20, 2017	$7,644	6,500,000	$0.00118
April 21, 2017	$16,464	14,000,000	$0.00118
April 25, 2017	$17,287	14,700,000	$0.00118
April 26, 2017	$26,600	26,600,000	$0.00100
May 1, 2017	$8,700	14,500,000	$0.00060
June 13, 2017	$1,200	10,000,000	$0.00012
June 16, 2017	$1,930	19,299,400	$0.00010
June 16, 2017	$1,300	11,000,000	$0.00012
June 20, 2017	$1,392	11,600,000	$0.00012
June 21, 2017	$2,314	23,139,900	$0.00010
June 22, 2017	$1,590	13,250,000	$0.00012
June 22, 2017	$1,470	12,250,000	$0.00012
June 26, 2017	$1,800	15,000,000	$0.00012
June 29, 2017	$1,980	16,500,000	$0.00012
July 3, 2017	$2,088	17,400,000	$0.00012
July 12, 2017	$2,088	17,400,000	$0.00012
July 13, 2017	$2,484	13,800,000	$0.00018
July 14, 2017	$3,374	19,000,000	$0.00018
July 18, 2017	$3,374	19,000,000	$0.00018
July 20, 2017	$3,582	19,900,000	$0.00018
July 24, 2017	$6,270	20,900,000	$0.0003
July 25, 2017	$6,870	22,900,000	$0.0003
July 28, 2017	$7,200	24,000,000	$0.0003
August 2, 2017	$7,200	24,000,000	$0.0003
August 4, 2017	$9,000	25,000,000	$0.00036
August 8, 2017	$11,119	26,475,000	$0.00042
August 11, 2017	$13,920	29,000,000	$0.00048
August 16, 2017	$12,810	30,500,000	$0.00042
August 22, 2017	$6,709	19,168,058	$0.00035
August 25, 2017	$11,200	32,000,000	$0.00035
August 31, 2017	$9,600	32,000,000	$0.0003
September 7, 2017	$9,900	36,000,000	$0.00028
September 15, 2017	$9,437	37,900,000	$0.00025
September 22, 2017	$9,910	39,800,000	$0.00025
September 28, 2017	$10,408	41,800,000	$0.00025
September 30, 2017 Total	$277,204	779,232,358

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	488,316	$   0.00450
April 4, 2016	$4,847	862,500	$   0.00562
April 7, 2016	$1,750	486,111	$   0.00360
April 14, 2016	$4,158	962,500	$   0.00432
April 15, 2016	$1,318	488,311	$   0.00270
April 26, 2016	$1,705	631,489	$   0.00270
May 4, 2016	$2,067	485,901	$   0.00426
May 31, 2016	$   828	230,003	$   0.00360
June 2, 2016	$9,120	1,500,000	$   0.00608
June 2, 2016	$4,401	1,467,017	$   0.00300
June 14, 2016	$5,847	1,461,795	$   0.00400
June 17,2016	$5,691	1,422,808	$   0.00400
June 29, 2016	$6,580	1,063,518	$   0.00618
August 23, 2016	$2,567	1,106,487	$   0.00232
August 29, 2016	$2,570	1,107,806	$   0.00232
September 6, 2016	$2,547	1,097,634	$   0.00232
September 20, 2016	$2,443	1,263,383	$   0.00194
September 26, 2016	$2,946	1,269,672	$   0.00232
September 28, 2016	$2,947	1,270,172	$   0.00232
September 30, 2016	$3,949	2,553,336	$   0.00154
October  7, 2016	$3,381	2,914,578	$   0.00116
October  14, 2016	$3,380	2,913,784	$   0.00116
October  21, 2016	$3,385	2,917,784	$   0.00116
October  26, 2016	$3,382	2,915,828	$   0.00116
October  31, 2016	$5,037	4,341,852	$   0.00116
November  7 , 2016	$5,015	4,323,647	$   0.00116
November  22, 2016	$5,513	4,753,008	$   0.00116
November  29, 2016	$5,515	4,754,647	$   0.00116
December 6, 2016	$4,058	3,497,965	$   0.00116
January 10, 2017	$6,301	6,301,150	$   0.00100
February 22, 2017	$4,290	3,575,000	$   0.00120
March 13, 2017	$4,080	3,400,000	$   0.00120
March 21, 2017	$4,920	4,100,000	$   0.00120
March 22, 2017	$5,160	4,300,000	$   0.00120
March 24, 2017	$5,460	4,550,000	$   0.00120
March 30, 2017	$5,645	4,800,000	$   0.00118
March 31, 2017	$5,939	5,050,000	$   0.00118
March 31, 2017 Total	$150,939	90,628,002

Schedule of Value of Options

Date	April 6, 2015	June 9, 2015	December 15, 2015	March 30, 2017
Options	102,000	50,000	43,000	29,000,000
Stock price grant date	$1.60	$0.40	$0.20	$0.002
Initial Exercise price	$1.60	$0.40	$0.20	$0.002
Modified Exercise price	$0.20	$0.20	$0.20	-
Expected life	5.0	5.0	5.0	5.0
Volatility	99%	99%	84%	120%
Risk-free rate	1.31%	1.74%	1.70%	1.93%
Calculated value	$120,778	$14,838	$5,736	$48,017
Modified value	$151,221	$16,347	$5,736	$48,017

Schedule of Option Activity

	Number of options		Weighted average exercise price
Outstanding, March 31, 2017		29,228,627	$	0.004
Granted		—		—
Exercised		—		—
Expired		—		—
Outstanding, September 30, 2017		29,228,627	$	0.004

XML

Subsequent Events (Tables)

1 Months Ended

6 Months Ended

12 Months Ended

Oct. 31, 2017

Sep. 30, 2017

Mar. 31, 2017

Subsequent Events Tables

Schedule of Conversions of Common Stock

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
October 3, 2017	$10,931	43,900,000	$0.000249
October 5, 2017	$7,582	30,448,193	$0.000249
Subsequent Total	$18,513	74,348,193

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 5, 2017	$6,233	5,300,000	$0.00118
April 10, 2017	$6,586	5,600,000	$0.00118
April 11, 2017	$6,880	5,850,000	$0.00118
April 18, 2017	$7,291	6,200,000	$0.00118
April 20, 2017	$7,644	6,500,000	$0.00118
April 21, 2017	$16,464	14,000,000	$0.00118
April 25, 2017	$17,287	14,700,000	$0.00118
April 26, 2017	$26,600	26,600,000	$0.00100
May 1, 2017	$8,700	14,500,000	$0.00060
June 13, 2017	$1,200	10,000,000	$0.00012
June 16, 2017	$1,930	19,299,400	$0.00010
June 16, 2017	$1,300	11,000,000	$0.00012
June 20, 2017	$1,392	11,600,000	$0.00012
June 21, 2017	$2,314	23,139,900	$0.00010
June 22, 2017	$1,590	13,250,000	$0.00012
June 22, 2017	$1,470	12,250,000	$0.00012
June 26, 2017	$1,800	15,000,000	$0.00012
June 29, 2017	$1,980	16,500,000	$0.00012
July 3, 2017	$2,088	17,400,000	$0.00012
July 12, 2017	$2,088	17,400,000	$0.00012
July 13, 2017	$2,484	13,800,000	$0.00018
July 14, 2017	$3,374	19,000,000	$0.00018
July 18, 2017	$3,374	19,000,000	$0.00018
July 20, 2017	$3,582	19,900,000	$0.00018
July 24, 2017	$6,270	20,900,000	$0.0003
July 25, 2017	$6,870	22,900,000	$0.0003
July 28, 2017	$7,200	24,000,000	$0.0003
August 2, 2017	$7,200	24,000,000	$0.0003
August 4, 2017	$9,000	25,000,000	$0.00036
August 8, 2017	$11,119	26,475,000	$0.00042
August 11, 2017	$13,920	29,000,000	$0.00048
August 16, 2017	$12,810	30,500,000	$0.00042
August 22, 2017	$6,709	19,168,058	$0.00035
August 25, 2017	$11,200	32,000,000	$0.00035
August 31, 2017	$9,600	32,000,000	$0.0003
September 7, 2017	$9,900	36,000,000	$0.00028
September 15, 2017	$9,437	37,900,000	$0.00025
September 22, 2017	$9,910	39,800,000	$0.00025
September 28, 2017	$10,408	41,800,000	$0.00025
September 30, 2017 Total	$277,204	779,232,358

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	488,316	$   0.00450
April 4, 2016	$4,847	862,500	$   0.00562
April 7, 2016	$1,750	486,111	$   0.00360
April 14, 2016	$4,158	962,500	$   0.00432
April 15, 2016	$1,318	488,311	$   0.00270
April 26, 2016	$1,705	631,489	$   0.00270
May 4, 2016	$2,067	485,901	$   0.00426
May 31, 2016	$   828	230,003	$   0.00360
June 2, 2016	$9,120	1,500,000	$   0.00608
June 2, 2016	$4,401	1,467,017	$   0.00300
June 14, 2016	$5,847	1,461,795	$   0.00400
June 17,2016	$5,691	1,422,808	$   0.00400
June 29, 2016	$6,580	1,063,518	$   0.00618
August 23, 2016	$2,567	1,106,487	$   0.00232
August 29, 2016	$2,570	1,107,806	$   0.00232
September 6, 2016	$2,547	1,097,634	$   0.00232
September 20, 2016	$2,443	1,263,383	$   0.00194
September 26, 2016	$2,946	1,269,672	$   0.00232
September 28, 2016	$2,947	1,270,172	$   0.00232
September 30, 2016	$3,949	2,553,336	$   0.00154
October  7, 2016	$3,381	2,914,578	$   0.00116
October  14, 2016	$3,380	2,913,784	$   0.00116
October  21, 2016	$3,385	2,917,784	$   0.00116
October  26, 2016	$3,382	2,915,828	$   0.00116
October  31, 2016	$5,037	4,341,852	$   0.00116
November  7 , 2016	$5,015	4,323,647	$   0.00116
November  22, 2016	$5,513	4,753,008	$   0.00116
November  29, 2016	$5,515	4,754,647	$   0.00116
December 6, 2016	$4,058	3,497,965	$   0.00116
January 10, 2017	$6,301	6,301,150	$   0.00100
February 22, 2017	$4,290	3,575,000	$   0.00120
March 13, 2017	$4,080	3,400,000	$   0.00120
March 21, 2017	$4,920	4,100,000	$   0.00120
March 22, 2017	$5,160	4,300,000	$   0.00120
March 24, 2017	$5,460	4,550,000	$   0.00120
March 30, 2017	$5,645	4,800,000	$   0.00118
March 31, 2017	$5,939	5,050,000	$   0.00118
March 31, 2017 Total	$150,939	90,628,002

XML

Summary of Significant Accounting Policies (Details Narrative)	6 Months Ended	12 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2016 shares	Mar. 31, 2013 $ / shares shares	Sep. 06, 2013 $ / shares shares	Sep. 05, 2013 $ / shares shares
Date Of Incorporation	Aug. 09, 2010
Cancellation of loans | $
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000		375,030,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ .001	$ .001		$ 0.001	$ 0.001	$ 0.001
Stock split ratio	0.05		0.01	4.1671
Cash and cash equivalent | $	$ 24,974	$ 40,903
Reserved common shares					195,002
Computer equipment	3 years
Options granted, number of shares		29,000,000	195,000
Dilutive Instruments, common stock warrants	9,446,533
Dilutive Instruments, common stock shares	29,195,000
Sale Agmt
Date of Agreement	Jul. 19, 2013
Cancellation of loans | $	$ 28,818
Shares sold by former officers	265,646
Shares returned to treasury	250,128
Shares agreed to cancel	131,261
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued	41,384
Series A Preferred Stock, shares issued	6,000,000
Stock Value | $	$ 123,973
Termination of agreement | $	20,000
Additional cash required | $	$ 2,000,000

XML

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160
Less: accumulated depreciation	(3,622)	(3,035)
Property and equipment, net	$ 1,538	$ 2,125

XML

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
Property And Equipment Details Narrative
Depreciation expense	$ 313	$ 431	$ 586	$ 863	$ 1,606
Computer equipment			3 years

XML

Securities Available For Sale (Details Narrative) - Collaboration Agmt	Sep. 30, 2017 shares
Securities available for sale	15,000,000
Ownership of Subsidiary	11.00%

XML

Intangible Assets (Details Narrative)	6 Months Ended
	Sep. 30, 2017 USD ($) shares
Collaboration Agmt
Date of Agreement	Jul. 11, 2017
Securities available for sale | shares	15,000,000
Payment for IP	$ 100,000
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued | shares	41,384
Series A Preferred Stock, shares issued | shares	6,000,000
Stock Value	$ 123,973
Impaired Assets	0
Asset Development Cost	$ 45,000
Asset Assign Agmt #2
Date of Agreement	Oct. 06, 2014
Common Stock, shares issued | shares	110,396
Common stock, value	$ 7,904,355
Impaired Assets	0
Impairment of intangible asset	$ 82,120

XML

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2017	Mar. 31, 2017
Payables and Accruals [Abstract]
Wages and taxes	$ 1,012,457	$ 829,231
Accrued interest	176,063	108,552
Total accrued expenses	$ 1,188,520	$ 937,783

XML

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2015	Mar. 31, 2016
Cancellation of loans
Due to related parties	$ 54,001		54,001		$ 49,395
Loans and interest received (repaid) from/to related parties			4,606	$ (37,812)
Interest expense, related party	(155)	$ (155)	(308)	$ (230)
Accrued expenses	1,188,520		1,188,520		937,783
Accounts payable related party	286,700		286,700		53,000
SH Loan #1
Due Date						Jan. 08, 2016
Loan from related party						$ 6,000
Interest Rate						8.00%
SH Loan #2
Loan from related party			6,280
Due to related parties	$ 12,280		$ 12,280		12,280
Interest Rate	8.00%		8.00%
Interest expense, related party			$ 1,211
Related Party Loans
Due to related parties	$ 350		350
Repayment of loans to related parties			40,160
Loans and interest received (repaid) from/to related parties			$ 36,300
Accrued expenses					14,450		$ 22,200
Employment Agmt
Date of Agreement			Sep. 06, 2013
Term of Agreement			2 years
Annual Compensation			$ 275,000
Options to purchase			1,500
Options to purchase, exercise price			$ 40
Bonus			$ 137,500
Earnings			275,000		275,000
Accrued Earnings			$ 737,611		$ 645,945
Collaboration Agmt
Date of Agreement			Jul. 11, 2017
Securities available for sale	15,000,000		15,000,000
Payment for IP			$ 100,000

XML

Note Payable (Details Narrative)	6 Months Ended
	Sep. 30, 2017 USD ($)
Note Payable #1
Date of Agreement	May 31, 2016
Convertible Note	$ 900,000
Interest Rate	10.00%
Due Date	Aug. 01, 2017
Interest Accrued	$ 120,082
Note Payable #2
Date of Agreement	Feb. 21, 2017
Convertible Note	$ 20,000
Interest Rate	8.00%
Due Date	Aug. 21, 2017
Interest Accrued	$ 969

XML

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument, Converted Amount		$ 277,208	$ 70,478
Convertible Prom Note #15
Date of Agreement					Feb. 05, 2015
Convertible Note					$ 54,000
Interest Rate					8.00%
Due Date					Nov. 09, 2015
Interest Accrued		0
Convertible Note, Balance		0		$ 59,799	$ 47,980
Debt Instrument, Converted Amount					$ 33,020
Common Stock, shares issued					619,652
Fee				Financing	Default
Fee Amount	$ 11,819			$ 11,819	$ 27,000
Convertible Prom Note #18
Date of Agreement					Mar. 09, 2015
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date					Jun. 23, 2017
Interest Accrued			0	0	$ 0
Convertible Note, Balance			8,838	0	16,215
Debt Instrument, Converted Amount			7,377		38,785
Debt Instrument, Interest Accrued, Converted Amount			$ 422		$ 5,135
Common Stock, shares issued			2,324,229		2,886,693
Convertible Prom Note #19
Date of Agreement			Mar. 26, 2015
Convertible Note			$ 29,680
Interest Rate			8.00%
Due Date			Mar. 23, 2016
Interest Accrued		4,602	$ 2,577
Convertible Note, Balance			18,751
Original Issue Discount			1,680
Debt Instrument, Converted Amount			$ 10,929
Common Stock, shares issued			796,236
Convertible Prom Note #21
Date of Agreement			May 05, 2015
Convertible Note			$ 68,900
Interest Rate			8.00%
Due Date			May 05, 2016
Interest Accrued				0
Convertible Note, Balance				0
Original Issue Discount			$ 3,900
Debt Instrument, Converted Amount			8,461	60,439
Debt Instrument, Interest Accrued, Converted Amount			$ 566	$ 6,839
Common Stock, shares issued			906,763	44,551,004
Convertible Prom Note #22
Date of Agreement				May 06, 2015
Convertible Note				$ 10,500
Interest Rate				8.00%
Due Date				Feb. 08, 2016
Interest Accrued		0
Convertible Note, Balance	$ 20,900	0		$ 15,750
Fee	Financing			Default
Fee Amount	$ 5,250	$ 5,150		$ 5,250
Convertible Prom Note #24
Date of Agreement				Aug. 28, 2015
Convertible Note				$ 15,000
Interest Rate				8.00%
Due Date				Aug. 28, 2016
Interest Accrued				$ 0
Convertible Note, Balance				0
Debt Instrument, Converted Amount				15,000
Debt Instrument, Interest Accrued, Converted Amount				$ 939
Common Stock, shares issued				4,351,619
Convertible Prom Note #25
Date of Agreement				Sep. 04, 2015
Convertible Note				$ 19,000
Interest Rate				8.00%
Due Date				Jun. 04, 2016
Interest Accrued	0
Convertible Note, Balance	0			$ 20,280
Fee				Financing
Fee Amount	1,280			$ 1,280
Convertible Prom Note #26
Date of Agreement					Dec. 29, 2015
Convertible Note					$ 57,378
Interest Rate					8.00%
Due Date					Jun. 23, 2017
Interest Accrued				0	$ 0
Convertible Note, Balance				$ 0	1,609
Debt Instrument, Converted Amount					59,934
Debt Instrument, Interest Accrued, Converted Amount					$ 1,222
Common Stock, shares issued					1,796,394
Fee					Default
Fee Amount					$ 4,165
Convertible Prom Note #27
Date of Agreement		Jan. 22, 2016
Convertible Note		$ 60,500
Interest Rate		10.00%
Due Date		Oct. 22, 2016
Interest Accrued		$ 0
Convertible Note, Balance		$ 0
Convertible Prom Note #28
Date of Agreement				Feb. 25, 2016
Convertible Note				$ 27,500
Interest Rate				8.00%
Due Date				Feb. 25, 2017
Interest Accrued				$ 0
Convertible Note, Balance				0
Original Issue Discount, unamortized				212
Debt Instrument, Converted Amount				16,745
Debt Instrument, Interest Accrued, Converted Amount				$ 1,380
Common Stock, shares issued				3,325,000
Convertible Prom Note #29
Date of Agreement				Mar. 24, 2016
Convertible Note				$ 7,500
Interest Rate				8.00%
Due Date				Mar. 24, 2017
Interest Accrued				$ 0
Convertible Prom Note #34
Date of Agreement				May 25, 2016
Convertible Note				$ 30,000
Interest Rate				8.00%
Due Date				May 25, 2017
Interest Accrued				$ 0
Convertible Note, Balance				$ 0
Fee				Financing
Fee Amount	8,107			$ 8,107
Convertible Prom Note #30
Date of Agreement				Jun. 08, 2016
Convertible Note				$ 84,250
Interest Rate				8.00%
Due Date				Jun. 08, 2017
Interest Accrued				$ 0
Convertible Note, Balance				$ 0
Fee				Financing
Fee Amount	$ 49,964			$ 49,964
Convertible Prom Note #32
Date of Agreement		Jun. 23, 2016
Convertible Note		$ 56,000
Interest Rate		8.00%
Due Date		Jun. 23, 2017
Interest Accrued		$ 5,695
Convertible Prom Note #35
Date of Agreement		Jul. 07, 2016
Convertible Note		$ 58,000
Interest Rate		8.00%
Due Date		Jul. 07, 2017
Interest Accrued		$ 2,869
Convertible Note, Balance		29,055
Debt Instrument, Converted Amount		28,945
Debt Instrument, Interest Accrued, Converted Amount		$ 1,902
Common Stock, shares issued		69,039,300
Convertible Prom Note #36
Date of Agreement		Oct. 20, 2016
Convertible Note		$ 32,000
Interest Rate		8.00%
Due Date		Oct. 20, 2017
Interest Accrued		$ 2,420
Convertible Prom Note #37
Date of Agreement		Nov. 17, 2016
Convertible Note		$ 56,000
Interest Rate		8.00%
Due Date		Jun. 23, 2017
Interest Accrued		$ 5,695
Convertible Prom Note #38
Date of Agreement		Jan. 05, 2017
Convertible Note		$ 335,000
Interest Rate		10.00%
Due Date		Oct. 05, 2017
Interest Accrued		$ 23,310
Convertible Note, Balance		0
Original Issue Discount		30,000
Convertible Prom Note #39
Date of Agreement				Feb. 20, 2017
Convertible Note				$ 563,028
Interest Rate				8.00%
Due Date				Oct. 25, 2017
Interest Accrued		3,297		$ 904
Convertible Note, Balance		122,086		124,066
Debt Instrument, Converted Amount		86,857		34,370
Debt Instrument, Interest Accrued, Converted Amount		$ 3,048		$ 1,124
Common Stock, shares issued		179,650,000		29,775,000
Convertible Prom Note #40
Date of Agreement		Feb. 21, 2017
Convertible Note		$ 15,000
Interest Rate		8.00%
Due Date		Oct. 25, 2017
Interest Accrued		$ 727
Convertible Prom Note #41
Date of Agreement		Feb. 22, 2017
Convertible Note		$ 59,799
Interest Rate		10.00%
Due Date		Oct. 25, 2017
Convertible Note, Balance		$ 0
Debt Instrument, Converted Amount		59,799
Debt Instrument, Interest Accrued, Converted Amount		4,795
Default Penalty to be recognized		$ 31,407
Common Stock, shares issued		311,043,058
Default Penalty to be recognized		$ 31,407
Convertible Prom Note #42
Date of Agreement		Feb. 22, 2017
Convertible Note		$ 20,900
Interest Rate		10.00%
Due Date		Oct. 22, 2017
Interest Accrued		$ 49
Convertible Note, Balance		13,207
Debt Instrument, Converted Amount		7,693
Debt Instrument, Interest Accrued, Converted Amount		18,607
Default Penalty to be recognized		$ 34,156
Common Stock, shares issued		219,500,000
Default Penalty to be recognized		$ 34,156
Convertible Prom Note #43
Date of Agreement		Apr. 04, 2017
Convertible Note		$ 71,457
Interest Rate		8.00%
Due Date		Jan. 08, 2018
Interest Accrued		$ 2,803
Convertible Prom Note #44
Date of Agreement		Apr. 18, 2017
Convertible Note		$ 115,000
Interest Rate		10.00%
Due Date		Jan. 30, 2018
Interest Accrued		$ 3,547
Original Issue Discount		11,500
Original Issue Discount, unamortized		$ 3,889

XML

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
Notes to Financial Statements
Change in value of derivative liability	$ (2,465,455)	$ (51,683)	$ (1,068,465)	$ (168,454)
Derivative expense			(249,457)
Debt Discounts, Conversion Features	681,011		681,011
Debt Discount, Unamortized	174,572		174,572
Derivative liabilities	1,912,905		1,912,905		$ 2,607,959
Derivative liabilities

XML

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Fair value allocation of proceeds
Warrant #10
Date	Mar. 30, 2017
Warrants	$ 9,200,000
Stock price on grant date	$ 0.002
Exercise price	$ 0.002
Expected life	5 years
Volatility	120.00%
Risk-free rate	1.96%
Calculated value	$ 15,278
Fair value allocation of proceeds	$ 45,466

XML

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	9,446,533
Beginning Balance, Average Exercise Price	$ 0.102
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	9,446,533	9,446,533
Ending Balance, Average Exercise Price	$ 0.102	$ 0.102

XML

Equity Transactions - Schedule of Value of Options (Details)	6 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Stock Option 7
Date of Issuance	Apr. 06, 2015
Options | shares	102,000
Stock price on grant date	$ 1.60
Exercise price	1.60
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.31%
Calculated value | $	$ 120,778
Modified value | $	$ 151,221
Stock Option 8
Date of Issuance	Jun. 09, 2015
Options | shares	50,000
Stock price on grant date	$ 0.40
Exercise price	0.40
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.74%
Calculated value | $	$ 14,838
Modified value | $	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015
Options | shares	43,000
Stock price on grant date	$ 0.20
Exercise price	0.20
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	84.00%
Risk-free rate	1.70%
Calculated value | $	$ 5,736
Modified value | $	$ 5,736
Stock Option 10
Date of Issuance	Mar. 30, 2017
Options | shares	29,000,000
Stock price on grant date	$ 0.002
Exercise price	$ 0.002
Expected life	5 years
Volatility	120.00%
Risk-free rate	1.93%
Calculated value | $	$ 48,017
Modified value | $	$ 48,017

XML

Equity Transactions - Schedule of Option Activity (Details) - shares	6 Months Ended	12 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Beginning Balance, number of shares	29,228,627
Beginning Balance, weighted average exercise price	0.004
Options granted, number of shares		29,000,000	195,000
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	29,228,627	29,228,627
Ending Balance, weighted average exercise price	0.004	0.004

XML

Equity Transactions (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Mar. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2016 shares	Mar. 31, 2013 $ / shares shares	Sep. 06, 2013 $ / shares shares	Sep. 05, 2013 $ / shares shares	Jul. 18, 2013 shares
Common Stock, Shares Authorized | shares	2,000,000,000		2,000,000,000		2,000,000,000		375,030,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ .001		$ .001		$ .001		$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized | shares	10,000,000		10,000,000		10,000,000
Preferred Stock, Par Value | $ / shares	$ .001		$ .001		$ .001
Series A Preferred Stock, Designated | shares										6,000,000
Common Stock, Issued | shares	880,678,573		880,678,573		101,446,215
Preferred Stock, Issued | shares	6,000,000		6,000,000		6,000,000
Stock split ratio			0.05			0.01	4.1671
Options granted, number of shares | shares					29,000,000	195,000
Debt Instrument, Converted Amount | $			$ 277,208	$ 70,478
Stock-based compensation | $
Common Stock Issued, Convertible Debt, Shares | shares			779,232,358
Adjustment to APIC | $			$ 502,027
Common stock to be issued | $	$ 100,000		100,000
2013 Stock Option Plan Amendment
Stock-based compensation | $			$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement			Apr. 06, 2015
Options granted, number of shares | shares			135,627
Exercise price | $ / shares			$ 1.60
Stock-based compensation | $			$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement			Aug. 04, 2015
Options granted, number of shares | shares			185,627
Exercise price | $ / shares			$ 0.40
Stock-based compensation | $			$ 47,463
Debt Conversion #65
Date of Issuance			Jan. 04, 2016
Common Stock, shares issued | shares			161,161
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 19,339
Debt Conversion #89
Date of Issuance			Apr. 01, 2016
Common Stock, shares issued | shares			488,316
Common Stock, price per share | $ / shares			$ .00450
Debt Instrument, Converted Amount | $			$ 2,197
Debt Conversion #90
Date of Issuance			Apr. 04, 2016
Common Stock, shares issued | shares			862,500
Common Stock, price per share | $ / shares			$ .00562
Debt Instrument, Converted Amount | $			$ 4,847
Debt Conversion #91
Date of Issuance			Apr. 07, 2016
Common Stock, shares issued | shares			486,111
Common Stock, price per share | $ / shares			$ .00360
Debt Instrument, Converted Amount | $			$ 1,750
Debt Conversion #92
Date of Issuance			Apr. 14, 2016
Common Stock, shares issued | shares			962,500
Common Stock, price per share | $ / shares			$ .00432
Debt Instrument, Converted Amount | $			$ 4,158
Debt Conversion #93
Date of Issuance			Apr. 15, 2016
Common Stock, shares issued | shares			488,311
Common Stock, price per share | $ / shares			$ .00270
Debt Instrument, Converted Amount | $			$ 1,318
Debt Conversion #94
Date of Issuance			Apr. 26, 2016
Common Stock, shares issued | shares			631,489
Common Stock, price per share | $ / shares			$ .00270
Debt Instrument, Converted Amount | $			$ 1,705
Debt Conversion #95
Date of Issuance			May 04, 2016
Common Stock, shares issued | shares			485,901
Common Stock, price per share | $ / shares			$ .00426
Debt Instrument, Converted Amount | $			$ 2,067
Debt Conversion #96
Date of Issuance			May 31, 2016
Common Stock, shares issued | shares			230,003
Common Stock, price per share | $ / shares			$ .00360
Debt Instrument, Converted Amount | $			$ 828
Debt Conversion #97
Date of Issuance			Jun. 02, 2016
Common Stock, shares issued | shares			1,500,000
Common Stock, price per share | $ / shares			$ .00608
Debt Instrument, Converted Amount | $			$ 9,120
Debt Conversion #98
Date of Issuance			Jun. 02, 2016
Common Stock, shares issued | shares			1,467,017
Common Stock, price per share | $ / shares			$ .00300
Debt Instrument, Converted Amount | $			$ 4,401
Debt Conversion #99
Date of Issuance			Jun. 14, 2016
Common Stock, shares issued | shares			1,461,795
Common Stock, price per share | $ / shares			$ .00400
Debt Instrument, Converted Amount | $			$ 5,847
Debt Conversion #100
Date of Issuance			Jun. 17, 2016
Common Stock, shares issued | shares			1,422,808
Common Stock, price per share | $ / shares			$ .00400
Debt Instrument, Converted Amount | $			$ 5,691
Debt Conversion #101
Date of Issuance			Jun. 29, 2017
Common Stock, shares issued | shares			1,063,518
Common Stock, price per share | $ / shares			$ .00618
Debt Instrument, Converted Amount | $			$ 6,580
Debt Conversion #102
Date of Issuance			Aug. 23, 2016
Common Stock, shares issued | shares			1,106,487
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,567
Debt Conversion #103
Date of Issuance			Aug. 29, 2016
Common Stock, shares issued | shares			1,107,806
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,570
Debt Conversion #104
Date of Issuance			Sep. 06, 2016
Common Stock, shares issued | shares			1,097,634
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,547
Debt Conversion #105
Date of Issuance			Sep. 20, 2016
Common Stock, shares issued | shares			1,263,383
Common Stock, price per share | $ / shares			$ .00194
Debt Instrument, Converted Amount | $			$ 2,443
Debt Conversion #106
Date of Issuance			Sep. 26, 2016
Common Stock, shares issued | shares			1,269,672
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,946
Debt Conversion #107
Date of Issuance			Sep. 28, 2016
Common Stock, shares issued | shares			1,270,172
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,947
Debt Conversion #108
Date of Issuance			Sep. 30, 2016
Common Stock, shares issued | shares			2,553,336
Common Stock, price per share | $ / shares			$ .00154
Debt Instrument, Converted Amount | $			$ 3,949
Debt Conversion #109
Date of Issuance			Oct. 07, 2016
Common Stock, shares issued | shares			2,914,578
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,381
Debt Conversion #110
Date of Issuance			Oct. 14, 2016
Common Stock, shares issued | shares			2,913,784
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,380
Debt Conversion #111
Date of Issuance			Oct. 21, 2016
Common Stock, shares issued | shares			2,917,784
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,385
Debt Conversion #112
Date of Issuance			Oct. 26, 2016
Common Stock, shares issued | shares			2,915,828
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,382
Debt Conversion #113
Date of Issuance			Oct. 31, 2016
Common Stock, shares issued | shares			4,341,853
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,037
Debt Conversion #114
Date of Issuance			Nov. 07, 2016
Common Stock, shares issued | shares			4,323,647
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,015
Debt Conversion #115
Date of Issuance			Nov. 22, 2016
Common Stock, shares issued | shares			4,753,009
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,513
Debt Conversion #116
Date of Issuance			Nov. 29, 2016
Common Stock, shares issued | shares			4,754,647
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,515
Debt Conversion #117
Date of Issuance			Dec. 06, 2016
Common Stock, shares issued | shares			3,497,966
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 4,058
Debt Conversion #118
Date of Issuance			Jan. 10, 2017
Common Stock, shares issued | shares			6,301,150
Common Stock, price per share | $ / shares			$ 0.00100
Debt Instrument, Converted Amount | $			$ 6,301
Debt Conversion #119
Date of Issuance			Feb. 22, 2017
Common Stock, shares issued | shares			3,575,000
Common Stock, price per share | $ / shares			$ 0.00120
Debt Instrument, Converted Amount | $			$ 4,290
Debt Conversion #120
Date of Issuance			Mar. 13, 2017
Common Stock, shares issued | shares			3,400,000
Common Stock, price per share | $ / shares			$ 0.00120
Debt Instrument, Converted Amount | $			$ 4,080
Debt Conversion #121
Date of Issuance			Mar. 21, 2017
Common Stock, shares issued | shares			4,100,000
Common Stock, price per share | $ / shares			$ 0.00120
Debt Instrument, Converted Amount | $			$ 4,920
Debt Conversion #122
Date of Issuance			Mar. 22, 2017
Common Stock, shares issued | shares			4,300,000
Common Stock, price per share | $ / shares			$ 0.00120
Debt Instrument, Converted Amount | $			$ 5,160
Debt Conversion #123
Date of Issuance			Mar. 24, 2017
Common Stock, shares issued | shares			4,550,000
Common Stock, price per share | $ / shares			$ 0.00120
Debt Instrument, Converted Amount | $			$ 5,460
Debt Conversion #124
Date of Issuance			Mar. 30, 2017
Common Stock, shares issued | shares			4,800,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 5,645
Debt Conversion #125
Date of Issuance			Mar. 31, 2017
Common Stock, shares issued | shares			5,050,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 5,939
Debt Conversion #126
Date of Issuance			Apr. 05, 2017
Common Stock, shares issued | shares			5,300,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 6,233
Debt Conversion #127
Date of Issuance			Apr. 10, 2017
Common Stock, shares issued | shares			5,600,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 6,586
Debt Conversion #128
Date of Issuance			Apr. 11, 2017
Common Stock, shares issued | shares			5,850,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 6,880
Debt Conversion #129
Date of Issuance			Apr. 18, 2017
Common Stock, shares issued | shares			6,200,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 7,291
Debt Conversion #130
Date of Issuance			Apr. 20, 2017
Common Stock, shares issued | shares			6,500,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 7,644
Debt Conversion #131
Date of Issuance			Apr. 21, 2017
Common Stock, shares issued | shares			14,000,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 16,464
Debt Conversion #132
Date of Issuance			Apr. 25, 2017
Common Stock, shares issued | shares			14,700,000
Common Stock, price per share | $ / shares			$ 0.00118
Debt Instrument, Converted Amount | $			$ 17,287
Debt Conversion #133
Date of Issuance			Apr. 26, 2017
Common Stock, shares issued | shares			26,600,000
Common Stock, price per share | $ / shares			$ 0.001
Debt Instrument, Converted Amount | $			$ 26,600
Debt Conversion #134
Date of Issuance			May 01, 2017
Common Stock, shares issued | shares			14,500,000
Common Stock, price per share | $ / shares			$ 0.00060
Debt Instrument, Converted Amount | $			$ 8,700
Debt Conversion #135
Date of Issuance			Jun. 13, 2017
Common Stock, shares issued | shares			10,000,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,200
Debt Conversion #136
Date of Issuance			Jun. 16, 2017
Common Stock, shares issued | shares			11,000,000
Common Stock, price per share | $ / shares			$ 0.00010
Debt Instrument, Converted Amount | $			$ 1,930
Debt Conversion #137
Date of Issuance			Jun. 16, 2017
Common Stock, shares issued | shares			19,299,400
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,300
Debt Conversion #138
Date of Issuance			Jun. 20, 2017
Common Stock, shares issued | shares			11,600,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,382
Debt Conversion #139
Date of Issuance			Jun. 21, 2017
Common Stock, shares issued | shares			23,139,900
Common Stock, price per share | $ / shares			$ 0.00010
Debt Instrument, Converted Amount | $			$ 2,314
Debt Conversion #140
Date of Issuance			Jun. 22, 2017
Common Stock, shares issued | shares			12,250,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,590
Debt Conversion #141
Date of Issuance			Jun. 22, 2017
Common Stock, shares issued | shares			13,250,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,470
Debt Conversion #142
Date of Issuance			Jun. 26, 2017
Common Stock, shares issued | shares			15,000,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,800
Debt Conversion #143
Date of Issuance			Jun. 29, 2017
Common Stock, shares issued | shares			16,500,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 1,980
Debt Conversion #144
Date of Issuance			Jul. 03, 2017
Common Stock, shares issued | shares			17,400,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 2,088
Debt Conversion #145
Date of Issuance			Jul. 12, 2017
Common Stock, shares issued | shares			17,400,000
Common Stock, price per share | $ / shares			$ 0.00012
Debt Instrument, Converted Amount | $			$ 2,088
Debt Conversion #146
Date of Issuance			Jul. 13, 2017
Common Stock, shares issued | shares			13,800,000
Common Stock, price per share | $ / shares			$ 0.00018
Debt Instrument, Converted Amount | $			$ 2,484
Debt Conversion #147
Date of Issuance			Jul. 14, 2017
Common Stock, shares issued | shares			19,000,000
Common Stock, price per share | $ / shares			$ 0.00018
Debt Instrument, Converted Amount | $			$ 3,374
Debt Conversion #148
Date of Issuance			Jul. 03, 2017
Common Stock, shares issued | shares			19,000,000
Common Stock, price per share | $ / shares			$ 0.00018
Debt Instrument, Converted Amount | $			$ 3,374
Debt Conversion #149
Date of Issuance			Jul. 20, 2017
Common Stock, shares issued | shares			19,900,000
Common Stock, price per share | $ / shares			$ 0.00018
Debt Instrument, Converted Amount | $			$ 3,582
Debt Conversion #150
Date of Issuance			Jul. 24, 2017
Common Stock, shares issued | shares			20,900,000
Common Stock, price per share | $ / shares			$ 0.0003
Debt Instrument, Converted Amount | $			$ 6,270
Debt Conversion #151
Date of Issuance			Jul. 25, 2017
Common Stock, shares issued | shares			22,900,000
Common Stock, price per share | $ / shares			$ 0.0003
Debt Instrument, Converted Amount | $			$ 6,870
Debt Conversion #152
Date of Issuance			Jul. 28, 2017
Common Stock, shares issued | shares			24,000,000
Common Stock, price per share | $ / shares			$ 0.0003
Debt Instrument, Converted Amount | $			$ 7,200
Debt Conversion #153
Date of Issuance			Aug. 02, 2017
Common Stock, shares issued | shares			24,000,000
Common Stock, price per share | $ / shares			$ 0.0003
Debt Instrument, Converted Amount | $			$ 7,200
Debt Conversion #154
Date of Issuance			Aug. 04, 2017
Common Stock, shares issued | shares			25,000,000
Common Stock, price per share | $ / shares			$ 0.00036
Debt Instrument, Converted Amount | $			$ 9,000
Debt Conversion #155
Date of Issuance			Aug. 08, 2017
Common Stock, shares issued | shares			26,475,000
Common Stock, price per share | $ / shares			$ 0.00042
Debt Instrument, Converted Amount | $			$ 11,119
Debt Conversion #156
Date of Issuance			Aug. 11, 2017
Common Stock, shares issued | shares			29,000,000
Common Stock, price per share | $ / shares			$ 0.00048
Debt Instrument, Converted Amount | $			$ 13,920
Debt Conversion #157
Date of Issuance			Aug. 16, 2017
Common Stock, shares issued | shares			30,500,000
Common Stock, price per share | $ / shares			$ 0.00042
Debt Instrument, Converted Amount | $			$ 12,810
Debt Conversion #158
Date of Issuance			Aug. 22, 2017
Common Stock, shares issued | shares			19,168,058
Common Stock, price per share | $ / shares			$ 0.00035
Debt Instrument, Converted Amount | $			$ 6,709
Debt Conversion #159
Date of Issuance			Aug. 25, 2017
Common Stock, shares issued | shares			32,000,000
Common Stock, price per share | $ / shares			$ 0.00035
Debt Instrument, Converted Amount | $			$ 11,200
Debt Conversion #160
Date of Issuance			Aug. 31, 2017
Common Stock, shares issued | shares			32,000,000
Common Stock, price per share | $ / shares			$ 0.0003
Debt Instrument, Converted Amount | $			$ 9,600
Debt Conversion #161
Date of Issuance			Sep. 07, 2017
Common Stock, shares issued | shares			36,000,000
Common Stock, price per share | $ / shares			$ 0.00028
Debt Instrument, Converted Amount | $			$ 9,900
Debt Conversion #162
Date of Issuance			Sep. 15, 2017
Common Stock, shares issued | shares			37,900,000
Common Stock, price per share | $ / shares			$ 0.00025
Debt Instrument, Converted Amount | $			$ 9,437
Debt Conversion #163
Date of Issuance			Sep. 22, 2017
Common Stock, shares issued | shares			39,800,000
Common Stock, price per share | $ / shares			$ 0.00025
Debt Instrument, Converted Amount | $			$ 9,910
Debt Conversion #164
Date of Issuance			Sep. 28, 2017
Common Stock, shares issued | shares			41,800,000
Common Stock, price per share | $ / shares			$ 0.00025
Debt Instrument, Converted Amount | $			$ 10,408
Stock Sub Agmt
Date of Agreement			Oct. 16, 2017
Warrants | $			$ 333,333,333
Exercise price | $ / shares			$ 0.0003
Expected life			5 years
Common Stock, Subscribed but Unissued | shares	333,333,333		333,333,333
Common stock to be issued | $	$ 100,000		$ 100,000
Warrant #10
Exercise Date			Mar. 30, 2017
Warrants | $			$ 9,200,000
Stock price on grant date | $ / shares			$ 0.002
Exercise price | $ / shares			$ 0.002
Expected life			5 years

XML

Commitments and Contingencies (Details Narrative)	6 Months Ended
	Sep. 30, 2017 USD ($) shares
Monthly Rent	$ 2,800
Contract
Date of Agreement	Jul. 08, 2016
Contract Duration	27 months
Contract Committment Value	$ 193,255
CannCodex
Date of Agreement	Apr. 01, 2017
Shares issued for services | shares	78,000,000
Loan payable	$ 15,300

XML

Subsequent Event (Details Narrative)	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2016	Mar. 31, 2013 $ / shares shares	Mar. 31, 2017 USD ($) $ / shares shares	Sep. 06, 2013 $ / shares shares	Sep. 05, 2013 $ / shares shares
Debt Instrument, Converted Amount			$ 277,208	$ 70,478
Common Stock, Par Value | $ / shares	$ .001		$ .001				$ 0.001	$ .001	$ 0.001	$ 0.001
Common Stock, Shares Authorized | shares	2,000,000,000		2,000,000,000				375,030,000	2,000,000,000	375,030,000	900,000
Stock split ratio			0.05			0.01	4.1671
Accrued expenses	$ 1,188,520		$ 1,188,520					$ 937,783
Consulting expenses	$ 95,375	$ 5,850	$ 100,000	$ 16,075
Consulting Agmt #2
Date of Agreement					Nov. 13, 2017
Consulting expenses					$ 7,000
Debt Conversion #165
Date of Issuance					Oct. 03, 2017
Debt Instrument, Converted Amount					$ 10,931
Common Stock, shares issued | shares					43,900,000
Common Stock, price per share | $ / shares					$ 0.00025
Debt Conversion #166
Date of Issuance					Oct. 05, 2017
Debt Instrument, Converted Amount					$ 7,582
Common Stock, shares issued | shares					30,448,193
Common Stock, price per share | $ / shares					$ 0.00025
Convertible Prom Note #45
Convertible Note					$ 34,500
Interest Rate					10.00%
Due Date					Aug. 03, 2018
Date of Issuance					Nov. 03, 2017
Original Issue Discount					$ 3,450